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A NOVEL ANTIBODY BASED CAPTURE MATRIX  
UTILIZING HUMAN SERUM ALBUMIN AND STREPTOCOCCAL PROTEIN G 
TO INCREASE CAPTURE EFFICIENCY OF BACTERIA  
CHRISTIE RENEE MCCABE 
ABSTRACT 
A novel capture matrix utilizing human serum albumin (HSA) and streptococcal 
Protein G (PG), which possesses an albumin binding domain (ABD), was used to 
immobilize antibodies for improved bacterial capture efficiency in immunoassays. 
Enzyme linked immunosorbent assays (ELISA) were used to characterize and optimize a 
specific protocol for the HSA-PG capture matrix; which revealed several critical factors 
that should be considered. The Fc binding domain, on PG, should have high affinity for 
the species of capture antibody used in the assay. Goat and rabbit species antibodies 
bound strongly to the Fc binding domain of PG. Displacement of the capture antibody, by 
the detector antibody should be avoided to reduce background signals. The Fc binding 
domain on PG should have equivalent or lower affinity for the detector antibody, when 
compared to the capture antibody. Goat species antibody, used as a detector antibody, did 
not displace the same-species capture antibody. ELISA analysis showed detection of 
Escherichia coli O157:H7 cells at 1.0 x 104 CFU/ml using HSA-PG and goat antibody 
raised against Escherichia coli O157:H7; unlabeled antibody was used for capture while 
HRP labeled antibody was used for detection. Studies were performed on an automated 
fiber optic biosensor, RAPTOR, which was used for the rapid detection of pathogens. 
 ix 
 
Biosensor assays showed detection of E. coli O157:H7 at 1.0 x 103 CFU/ml in PBS and 
1.0 x 105 CFU/ml in homogenized ground beef supernatant. Capture efficiency of the 
HSA-PG capture matrix was studied using the biosensor and GFP-E. coli O157:H7. The 
amount of cells captured was less than one percent of the sample concentration. This 
limit of detection and capture efficiency was comparable to the streptavidin-biotin 
capture matrix.     
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INTRODUCTION 
 
Objective  
Fluorescent immunoassays have been growing in popularity for use in the field of 
pathogen detection. In 1984, Hirschfeld patented the use of evanescent wave and optical 
fiber in an immunoassay format to detect fluorescent labeled analytes (15). Since this 
invention, optical fiber and fluorescent immunoassay have been developed for use in 
biosensor technology to rapidly detect pathogens in environmental samples (6, 19, 23). 
Biosensors detect targets that have been captured by a matrix of capture molecules 
attached to a solid surface such as an optical fiber or waveguide. However, antibody 
based biosensor assays are plagued by poor capture efficiency and low sensitivity (36). 
The goal of this research was to orient the capture antibody to enhance capture efficiency 
of a target bacterium. This increase in capture efficiency may improve assay sensitivity 
so that fewer bacterial cells are required for positive detection by the biosensor. This 
improved detection would benefit the public directly by promoting advances in food 
safety inspections and homeland security efforts. In order to investigate the hypothesis 
that orientation of antibodies would improve detection sensitivity, a novel capture matrix 
that presented antibodies in a uniform formation on a solid surface was developed and 
then examined to assess improvements made to capture efficiency or assay sensitivity.     
 
 
 Biosensor Assay 
A sandwich biosensor assay consists of three phases as shown in Figure 1. The 
purpose of the Capture Phase is to immobilize antibodies which are specifically able to 
capture the target antigen. The Sample Phase is the introduction of liquid containing 
whole bacterial cells or small toxins. The sample may come from a variety of liquids such 
as homogenized ground meat supernatant, environmental water or phosphate buffered 
saline. The purpose of the Reporter Phase is to detect captured antigens by using a 
fluorescently labeled detector antibody specific for the target. The fluorescently labeled 
antibody is excited by a 635 nm laser focused through the core of the waveguide. The 
evanescent wave produced by the laser penetrates the surface of the waveguide to excite 
fluorophores within 100-1000 nm of the waveguide surface (11, 23). Emissions from the 
fluorophore are recoupled into the optical fiber and converted to picoamperes (pA) by a 
photodiode. Ultimately, the biosensor is a dedicated fluorometer that is able to collect and 
quantitate emitted wavelengths above 650 nm. Any of these phases can be modified in 
order to produce a more efficient and sensitive biosensor assay.  
 
FIGURE 1. Biosensor Phases  
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Streptavidin-Biotin 
Currently, biosensor capture surfaces are coated with a large homo-tetrameric 
protein isolated from the bacterium Streptomyces avidinii known as streptavidin (39). 
Streptavidin (60kDa) has an extremely high binding affinity (Ka = 2.5 x1013) for the 
much smaller vitamin H (244 Da), more commonly called biotin (13). Streptavidin-biotin 
conjugation is widely used in microbiology and immunology due to this strong non-
covalent interaction. Streptavidin has four subunits and each subunit can bind one biotin 
molecule. In solution, one streptavidin molecule can bind up to four biotin molecules 
simultaneously and with equivalent affinity (22). This strong binding ability has been 
utilized in a variety of assays, e.g., biotinylation of nucleic acids, amino acids and 
antibodies. The biotinylation enables the capture of targets by indirectly attaching them to 
a streptavidin coated surface. Biotinylated antibodies, anchored via streptavidin to fiber 
optic waveguides, have been reported in a number of recent biosensor manuscripts (6, 19, 
36).  
Random Antibody Orientation 
Biotin can be attached to the carbohydrate moiety found on the crystallizable 
fragment (Fc) region, or to the primary amines (-NH2) located on the numerous lysine 
residues found on the Fc, and antigen binding fragment (Fab) regions of an 
immunoglobulin G (IgG) molecule (16, 31). Hnatowich’s method uses succinimidyl-6-
(biotinamido) hexanoate (NHS-LC-Biotin) to biotinylate lysine residues on an IgG 
molecule (6). This labeling method results in a random orientation of the antibody, tilted 
at various angles on the waveguide surface, with paratopes that are not aligned for 
antibody-antigen interaction (31). As depicted in Figure 2, the antibodies are not oriented 
 efficiently on the waveguide for antigen capture. If the antibody is angled slightly, or laid 
on its side the antigen binding site is not likely to come into contact with the antigen, 
which results in missed capture opportunities. These missed opportunities may lead to 
poor bacterial capture efficiency by the capture matrix.   
 
Capture IgG
Biotin
Streptavidin
Waveguide  
 
 
FIGURE 2. Orientation of Biotinylated Antibody on a Streptavidin Coated Waveguide  
 
 
Human Serum Albumin 
Working with human serum albumin (HSA) has many advantages beyond its 
common usage as a blocking agent in ELISA protocols (5). HSA (66 kDa) is an 
inexpensive transporter protein found abundantly in human plasma (5 g/ 100 ml). The 
ability of HSA to transport molecules to target organs has been exploited to deliver 
therapeutic drugs in vivo (38). Like many species of albumin, the structure of HSA is a 
single asymmetrical polypeptide contained in three, almost identical, homologous 
domains resultant from gene multiplication (8, 38). This simple albumin structure allows 
for high affinity and rapid binding to ligands, such as the albumin binding domain of 
streptococcal PG (29). The efficient coating of polystyrene surfaces by HSA removes the 
need for any additional blocking step, which allows the assay to be performed quickly 
(18).    
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Streptococcal Protein G 
Lancefield group C and G streptococcal strains produce transmembrane bound 
Protein G (PG) to evade host immune responses. Membrane-bound PG binds to the Fc 
domain of an opsonizing antibody in vivo, which prevents C1q, a subcomponent of the 
complement system, from recognizing the antibody and initiating the classical pathway 
(27). PG is a highly versatile protein; however, almost all commercially available PG is 
in a recombinant form. This recombinant form lacks the albumin binding domain located 
on the amino terminus of PG (17, 20, 29, 37). The albumin binding domain, if left intact, 
binds to serum albumin, making the protein inefficient at extracting and purifying 
antibodies from blood samples. The albumin binding domain of PG has been used to 
anchor antibody fragments to HSA coated polystyrene ELISA wells (18). Native PG, 
containing the albumin binding domain, can be used as an anchor to polystyrene surfaces 
that have been non-covalently coated with HSA, such as a fiber optic waveguide or 
ELISA wells. PG has a high amount of secondary structure and contains a hydrophobic 
core, which makes it a very heat-stable protein (7). The robust nature of PG contributes 
greatly to its appeal for use in biosensor assays.  
In addition to the albumin binding domain, PG (65 kDa) has three identical IgG 
binding domains near the carboxyl terminus, which is structurally opposite from the 
albumin binding domain (14, 17, 20, 28, 30, 37). Only one of the three IgG binding 
domains, the most distal, has shown the ability to bind the carboxyl terminus of the heavy 
chain of intact IgG, or to the Fab region of fragmented IgG. This binding occurs without 
large conformational changes in the structure of either participant (7). PG has a high 
binding affinity (Ka = 5-10 x 1010) for the heavy chain of the Fc domain of IgG 
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belonging to several different species, including goat, rabbit and human. The affinity of 
the PG Fc binding domain is minimal for mouse IgG (1, 4), and completely absent for 
chicken IgG (1, 14). This species specificity is due to the relatively conserved nature of 
the four gamma (γ) chains of the IgG molecule (14). Table 2 shows the relative affinities 
of several species of IgG.    
 
 
Species of Polyclonal 
Immunoglobulin 
Amount (ng) of Ig Required 
to Give a 50% Inhibition In 
Competitive ELISA 
Protein G 
Rabbit  151 
Goat  217 
Human  556 
Mouse  1020 
Chicken    - 
 
– Indicates Species Not Reactive with Fc Binding Domain on PG 
TABLE 1. Species Specificity of the Fc Binding Domain on PG (14) 
 
The PG-IgG Complex 
The binding of the PG IgG-binding domain to the carboxyl terminus of the heavy 
chain of IgG involves a large amount of surface area on both molecules, creating a 
binding affinity comparable to antigen-antibody complexes (Ka = 5-10 x 1011) (7). In 
addition to multiple hydrogen bonds and van der Waals attractions, the bound complex 
remains intact in solution due to a hydrophobic area, created by the interaction of side 
chains of charged residues. This conformational binding was observed while the 
molecule was in crystal form, as well as in solution, indicating that liquid would not 
denature the PG-IgG complex (7).  
 Antibody Orientation by HSA-PG 
The uniform orientation of an antibody on a solid surface increases its activity by 
promoting interactions between antigen, and antigen binding sites, as compared to 
random antibody orientation (40). Streptococcal PG binds specifically to the carboxyl 
terminus of the Fc region of an IgG molecule, which causes the Fab region to face 
outward (21, 25). This uniform orientation of immobilized IgG on HSA-PG can be 
attached to a solid surface for use in a biosensor assay or ELISA, and may lead to 
increased capture efficiency and sensitivity. PG binding to the Fc domain of an IgG 
molecule dictates the orientation of the antibody when attached to an albumin protein 
coated surface (7).    
 
Capture IgG
Protein G
HSA
Waveguide  
FIGURE 3. Orientation of Antibody on a HSA-PG Coated Waveguide Surface  
 
Capture Efficiency 
Recently, the capture efficiency of evanescent waved based biosensor assays 
using a streptavidin-biotin-IgG capture matrix has been under review (36). Escherichia 
coli O157:H7 expressing green fluorescent protein was used to quantitate target cell 
capture on planar and cylindrical waveguides using an automated and manual biosensor. 
Capture efficiencies were inversely related to the concentration of sample introduced into 
the matrix (36). One possible explanation for the poor capture efficiency was the random 
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orientation of capture antibody on the waveguide surface. Random antibody orientation 
reduces antibody activity when the antibody is attached to a sold surface (24, 40). 
Capture efficiency may be improved by replacing the streptavidin-biotin-IgG capture 
matrix with an HSA-PG-IgG capture matrix, which uniformly orients the capture 
antibody to increase interactions with the targeted antigen.  
Hypothesis 
A novel capture matrix consisting of human serum albumin, streptococcal Protein 
G and capture antibody (HSA-PG-IgG) would uniformly orient capture antibodies on a 
solid surface, increasing capture efficiency of bacteria. More efficient bacterial capture 
would result in a higher signal-to-noise ratio, enhancing sensitivity of the assay. 
 9 
 
 
 
MATERIALS AND METHODS 
Bacterial Strains 
Escherichia coli O157:H7 was provided by the Massachusetts Department of 
Public Health State Laboratory Institute (Jamaica Plain, MA), and was used as the target 
antigen in all specificity and sensitivity studies. This environmental strain was recovered 
from taco meat distributed at a county fair, which resulted in an outbreak of food 
poisoning in Massachusetts. The strain was received by our laboratory in December 1998 
and was stored at -80ºC in sterile glycerol. A green fluorescent protein expressing stock 
of Escherichia coli O157:H7 ATCC#35150 (GFP-E. coli O157:H7) was used in all 
capture efficiency studies. The 5.4 kb GFP-encoded plasmid encoded ampicillin 
resistance and was regulated by an arabinose promoter which was activated by 
specialized media described in the Media and Culture Conditions section (36). 
 Escherichia coli K-12 was purchased from the American Type Culture 
Collection (ATCC#23590). E. coli K-12 was used as a negative control in all specificity 
and sensitivity studies.  
Buffers 
Sodium phosphate-buffered saline, 0.1 M and pH 7.4, (PBS) contained 3.2 g 
NaH2PO4, 20.6 g Na2HPO4 and 8 g NaCl per liter of filter (0.22 μm) sterilized water 
(Millipore; Billerica, MA). PBS with 0.05% Tween 20 (PBST) was used to remove any 
unbound reagents during rinsing steps.  
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Media and Culture Conditions 
Stock Cultures 
Cultures of E. coli O157:H7 and E. coli K-12 were grown on tryptic soy agar 
(TSA) for 18 hours at 37ºC, then stored at 4ºC for up to two weeks before being used to 
prepare sample cultures. GFP expressing E. coli O157:H7 (GFP-E. coli O157:H7) was 
maintained on Luria Bertani (LB) media containing 100 μg/ml ampicillin (AMP) and 5 
mg/ml arabinose (ARA) (LB+AMP+ARA). After 18 hours of growth at 37ºC the 
LB+AMP+ARA plates were inverted and stored at 4ºC for up to two weeks before being 
used to prepare sample broth cultures. All media was purchased from Becton Dickinson 
(Franklin Lakes, NJ) and was reconstituted and sterilized according to the manufacturer’s 
directions.  
Sample Cultures 
A single colony from a TSA plate was used to prepare a broth culture of E. coli 
O157:H7 or E. coli K-12 in tryptic soy broth (TSB). A single colony from an 
LB+AMP+ARA plate was used to prepare a broth culture of GFP- E. coli O157:H7 in 
LB+AMP+ARA broth. Broths were purchased from Becton Dickinson (Franklin Lakes, 
NJ) and were reconstituted and sterilized according to the manufacturer’s directions. A 
broth culture used in an experiment was grown in 10 ml of appropriate broth in a 50 ml 
conical tube for 18 hours at 37ºC with shaking at 200 r.p.m. The culture was then diluted 
(1:100) in fresh broth and returned to the shaking incubator for 4-6 hours until an optical 
density at 600 nm (OD600) of 0.6-1.0 was reached. Optical densities were measured using 
a DU®-64 spectrophotometer (Beckman, Fullerton, CA). The sample culture was serially 
diluted in PBS for use in an assay. The bacterial dilution was maintained at 24ºC in PBS 
 11 
 
for one hour, and then it was vortexed for twenty seconds using a Fisher Vortex Genie 2 
(Fisher Scientific; Suwanee, GA) to homogenize the cell culture. Once a homogeneous 
solution was reached, the bacterial dilution was added to the assay.  
The cell concentration for each sample culture was determined using viable count. 
One hundred microliters of GFP-E. coli O157:H7 was plated onto an LB+AMP+ARA 
plate, then incubated for 18 hours at 37ºC to allow growth of colonies. E. coli O157:H7 
and K-12 were similarly plated onto TSA to obtain viable counts. Sorbitol-MacConkey 
agar (SMAC) (Remel; Lenexa, KS) was used to recover and presumptively differentiate 
between E. coli O157:H7 and K-12 colonies. E. coli O157:H7 was unable to ferment 
sorbitol and produced colorless colonies on the SMAC plate. Alternatively, E. coli K-12 
was able to ferment sorbitol and produced pink or purple colonies on the SMAC plate.  
Capture Matrix Proteins 
 Albumins 
Ovalbumin (OVA) and human serum albumin (HSA) fraction V (96-99% purity 
by agarose gel electrophoresis) was purchased from Sigma-Aldrich (St. Louis, MO). 
Bovine serum albumin (BSA) was purchased from Fisher Scientific (Suwanee, GA). 
Lyophilized albumin crystals were rehydrated in 50% (v/v) glycerol, and 40 μl aliquots 
were stored at -20ºC in microfuge tubes. Working dilutions were prepared in PBS. 
Protein G and Streptavidin 
Native Protein G (PG) from Streptococcus species was purchased from 
Calbiochem (San Diego, CA). Streptavidin and PG lacking the albumin binding domain 
(recombinant PG) were purchased from Sigma-Aldrich. These lyophilized proteins were 
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rehydrated to 1.0 mg/ml in PBS, and 40 μl aliquots were stored at -20ºC in microfuge 
tubes. Working dilutions were prepared in PBS. 
Antibodies  
Lyophilized goat polyclonal antibody raised against E. coli O157:H7 and horse 
radish peroxidase labeled (HRP) labeled, biotin labeled or unlabeled (KPL; Gaithersburg, 
MD), was rehydrated in 50% (v/v) glycerol to 1.0 mg/ml. Mouse monoclonal antibodies, 
isotype IgG3, raised against E. coli O157:H7 were purchased from Abcam (Cambridge, 
MA), Biodesign International (Saco, ME), U.S. Biological (Swampscott, MA) and 
Fitzgerald (Concord, MA), and were diluted to 0.1 mg/ml in 50% (v/v) glycerol. 
Lyophilized mouse monoclonal antibody raised against rabbit or goat immunoglobulin; 
and HRP labeled, goat polyclonal antibody raised against mouse immunoglobulin; and 
rabbit polyclonal antibody raised against goat immunoglobulin; and HRP labeled or 
unlabeled rabbit (Jackson Immuno Research; West Grove, PA), was rehydrated in 50% 
(v/v) glycerol to 1.0 mg/ml. Lyophilized rabbit polyclonal antibody raised against PG 
(Abcam; Cambridge, MA), and lyophilized chicken polyclonal antibody raised against 
mouse immunoglobulin and HRP labeled (U.S. Biological; Swampscott, MA) was 
rehydrated in 50% (v/v) glycerol to 1.0 mg/ml. To avoid protein degradation each 
antibody was divided into 40 μl aliquots which were stored at -20ºC. Frozen antibody 
aliquots were used one time and never refrozen. Chicken polyclonal antibody raised 
against mouse immunoglobulin and HRP labeled (Aves Labs; Tigard, OR) was stored at 
4ºC. 
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Antibody Labeling  
Cy5 Antibody Labeling Column 
A column, used to separate unbound dye from labeled antibody, was prepared 
twenty four hours before labeling. In a 50 ml conical tube 1.4 g Bio-Gel P-10 fine (Bio-
Rad, Hercules, CA) was saturated with 20 ml PBS containing 0.02% (v/v) NaN3 (PBS-
NaN3). The gel was allowed to hydrate at 24ºC for 4 hours. A 20 ml Econo Pac column 
(Bio-Rad) was secured to a column stand and the end was snapped off. The Bio-Gel mix 
was thinned by the addition of 40 ml PBS-NaN3. After inverting the conical tube the 
slurry was transferred by pipette into the purification column. The gel was allowed to 
settle and excess buffer was drained. Once the gel settled, a frit was applied on top of the 
gel bed. A thin layer of PBS-NaN3 was applied to keep the frit moist. The column was 
then stored at 4ºC for twenty-four hours.  
Cy5 Antibody Labeling Procedure 
Antibody labeling was performed using a cyanine 5 dye (Cy5) labeling kit 
(Fluorolink™Cy5™Reactive Dye 5-pack, Amersham Life Sciences; Arlington Heights, 
IL). Lyophilized goat polyclonal antibody raised against E. coli O157:H7 was rehydrated 
in sodium carbonate buffer [0.1 M, pH 9.3] to 1.0 mg/ml. The antibody solution was 
transferred to a tube containing Cy5 reactive dye. The tube was capped and protected 
from light while it was incubated for one hour at 24ºC. The contents of the reaction tube 
were transferred by pipette onto the column frit. The contents were flushed from the frit 
by the addition of PBS, and clear liquid was collected as waste. The first of two blue 
bands observed moving through column was collected in an amber microfuge tube as 
labeled antibody. The second blue band consisted of unbound Cy5, and was discarded as 
 waste. The purification column was rinsed for 30 minutes with PBS-NaN3, then secured 
and stored at 4ºC for reuse within three months. The concentrations of antibody and Cy5 
dye in the labeled product were determined by measuring the absorbance at 280 nm 
(A280) and 650 nm (A650), respectively; and applying the Beer-Lambert Law, which 
explains the linear relationship between absorbance and concentration of the absorbing 
substance.  These concentrations were also used to determine the protein to dye ratio, 
which was the amount of dye particles conjugated to each protein molecule. 
Absorbencies were measured using a DU®-64 spectrophotometer (Beckman; Fullerton, 
CA). 
 
 
Concentration of Antibody (M) =    (A280 – (0.05 x A650))_ 
                                                     1 cm x 170,000 M-1 cm-1  
 
Concentration of Cy5 (M) =           (A650)                  _ 
                                            1 cm x 250,000 M-1 cm-1  
 
Dye to Protein Ratio = [Antibody (M)] 
                                  [Cy5 (M)] 
 
 
TABLE 2. Equations for Cy5 Labeling of Antibody  
 
DyLight™649 Antibody Labeling Procedure 
Antibody labeling was performed using a DyLight™ antibody labeling kit (Pierce 
Biotechnology; Rockford, IL). The labeling buffer [50 mM sodium borate pH 8.8] was 
prepared by combining 925 μl of PBS with 75μl of sodium borate buffer [67 mM]. Five 
hundred microliters of labeling buffer was added to 1.0 mg of lyophilized goat polyclonal 
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 antibody raised against E. coli O157:H7 to obtain a concentration of 2.0 mg/ml. The 
rehydrated antibody was transferred to a vial containing DyLight™649 reactive dye. The 
vial was gently inverted for ten seconds, and then centrifuged for thirty seconds to 
concentrate the protein at the bottom of the vial. The tube was protected from light and 
incubated for one hour at 24ºC. Two purification spin columns were placed inside two 
collection tubes and four hundred microliters of purification resin was added to each of 
the spin columns. The spin columns were centrifuged for 45 seconds at 1,000 x g to 
remove excess storage buffer, then the collection tubes were replaced by new tubes to 
collect the purified protein. Labeled antibody was evenly divided into the two spin 
columns, and then the columns were centrifuged for 45 seconds at 1,000 x g to separate 
unbound fluorophore from labeled antibody. The contents of the two collection vials 
were combined, and the concentrations of antibody and dye in the labeled product were 
determined by measuring the absorbance at 280 nm (A280) and 654 nm (A654), 
respectively. The Beer-Lambert Law was applied to these values. These concentrations 
were used to determine the protein to dye ratio, which was the amount of dye particles 
conjugated to each protein molecule. Absorbencies were measured using a DU®-64 
spectrophotometer (Beckman; Fullerton, CA). 
 
 
Concentration of Antibody =    (A280 – (0.0371 x A654))_x Dilution Factor 
                                               210,000 M-1 cm-1  
 
Dye to Protein Ratio =           (A654) x Dilution Factor                _ 
                             [Antibody] x 250,000 M-1 cm-1  
 
TABLE 3. Equations for DyLight™649 Labeling of Antibody  
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ELISAs 
PG Fc Binding Domain Specificity Assays 
One hundred microliters of HSA [0.5 or 1.0 μg/ml] was added to wells of a 96 
well Nunc Immuno plate and allowed to incubate for 18 hours at 4ºC to determine the 
functionality and specificity of the Fc binding domain of PG. After incubation, the plate 
was washed three times with PBST using an ELx50 Auto Strip Washer (Bio-Tek 
Instruments, Inc.; Winooski, VT). One hundred microliters of native PG [0 - 2.5 μg/ml] 
was added to albumin coated wells and allowed to incubate for 60 minutes at 24ºC. The 
plate was then washed three times with PBST. For competitive ELISAs, mouse 
monoclonal or goat polyclonal antibodies raised against rabbit immunoglobulin and 
labeled with HRP was mixed in equal concentrations [0 - 1.0 μg/ml] in a microfuge tube, 
with unlabeled mouse monoclonal or goat polyclonal antibody raised against E. coli 
O157:H7. One hundred microliters of the antibody combination was transferred into the 
ELISA well, and was incubated for 30 minutes at 24ºC. The plate was then washed three 
times with PBST. For indirect ELISAs, 100 μl of primary antibody [1.0 μg/ml], rabbit 
polyclonal antibody raised against goat immunoglobulin or goat polyclonal antibody 
raised against E. coli O157:H7, was added to the wells, and was incubated for 30 minutes 
at 24ºC. The plate was then washed three times with PBST. One hundred microliters of 
mouse monoclonal antibody raised against rabbit or goat immunoglobulin and HRP 
labeled [0.1 or 0.5 μg/ml], was added to the ELISA wells, and was incubated for 30 
minutes at 24ºC. The plate was then washed three times with PBST. A QuantaBlu™ 
Fluorogenic Peroxidase Substrate Kit (Pierce; Rockford, IL) was used to activate the 
peroxidase activity of antibodies labeled with HRP. Signals were detected and quantified 
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using a Spectra Max Gemini XS Microplate Fluorometer (Molecular Devices; Sunnyvale, 
CA) with excitation, emission, and cutoff wavelengths set at 340nm, 470nm and 455, 
respectively.   
PG Albumin Binding Domain Functionality and Specificity Assays 
One hundred microliters of HSA, ovalbumin (OVA) or bovine serum albumin 
(BSA) [0.5, 1 or 5 μg/ml] was added to a 96 well Nunc Immuno plate and allowed to 
incubate for 18 hours at 4ºC to determine the functionality and specificity of the albumin 
binding domain of PG. After incubation, the plate was washed three times with PBST 
using an ELx50 Auto Strip Washer (Bio-Tek Instruments, Inc.; Winooski, VT). One 
hundred microliters of native or recombinant PG [0-5 μg/ml] was added to the albumin 
coated wells, and allowed to incubate for 8 or 60 minutes at 24ºC. The plate was then 
washed three times with PBST. One hundred microliters of primary antibody [1.0 μg/ml], 
rabbit polyclonal antibody raised against PG or goat immunoglobulin was added to wells, 
and allowed to incubate for 30 minutes at 24ºC. The plate was then washed three times 
with PBST. One hundred microliters of mouse monoclonal antibody raised against rabbit 
immunoglobulin and HRP labeled [0.1 or 0.5 μg/ml] was added to wells, and was 
incubated for 30 minutes at 24ºC. The plate was then washed three times with PBST, and 
then analyzed for fluorescence using a QuantaBlu™ Fluorogenic Peroxidase Substrate 
Kit (Pierce; Rockford, IL) to activate the peroxidase activity of antibodies labeled with 
HRP. Signals were detected and quantified using a Spectra Max Gemini XS Microplate 
Fluorometer (Molecular Devices; Sunnyvale, CA) with excitation, emission, and cutoff 
wavelengths set at 340nm, 470nm and 455, respectively.   
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Direct Assays for Detection of E. coli O157:H7   
One hundred microliters of HSA [0 - 80 μg/ml] was added to a 96 well Nunc 
Immuno Plate (Fisher Scientific; Suwanee, GA), and was incubated for 18 hours at 4ºC to 
capture E. coli O157:H7 for detection by ELISA. After incubation, the plate was washed 
three times with PBST using an ELx50 Auto Strip Washer (Bio-Tek Instruments, Inc.; 
Winooski, VT). Native or recombinant PG [0-10 μg/ml] was added to HSA coated wells, 
and was incubated for 30 minutes at 24ºC. The plate was then washed three times with 
PBST. Capture antibody [0-5.0 μg/ml], goat polyclonal antibody raised against E. coli 
O157:H7, was added to wells, and was incubated for 30 minutes at 24ºC. The plate was 
then washed three times with PBST. One hundred microliters of E. coli O157:H7 or K-12 
was added to wells, and was incubated for 30 minutes at 24ºC; and then the plate was 
washed three times with PBST. One hundred microliters of mouse monoclonal or goat 
polyclonal antibody, raised against E. coli O157:H7 and HRP labeled [0.1 μg/ml], was 
added to wells, and was incubated for 30 minutes at 24ºC. The plate was then washed 
three times with PBST, and analyzed for fluorescence using a QuantaBlu™ Fluorogenic 
Peroxidase Substrate Kit (Pierce; Rockford, IL) to activate the peroxidase activity of 
antibodies labeled with HRP. Signals were detected and quantified using a Spectra Max 
Gemini XS Microplate Fluorometer (Molecular Devices; Sunnyvale, CA) with excitation, 
emission, and cutoff wavelengths set at 340nm, 470nm and 455, respectively.   
Statistical Analysis 
A one-way ANOVA with Dunnett's post test was performed using GraphPad 
InStat 3.00 (San Diego, CA) for all ELISAs. Paired data, in normal Gaussian distribution, 
was analyzed using a t test with a two tailed P value. Statistically significant P values (< 
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0.05) were noted on the graphs to aid in the analysis of the data. Raw data was analyzed 
using Microsoft Excel.     
RAPTOR ASSAYS 
Coupon Preparation 
Four polystyrene waveguides, of approximately 38 mm in length, were sonicated 
in isopropanol for thirty seconds, and then rinsed in 250 ml of water that was filter (0.22 
μm), and ultraviolet light sterilized, using a Milli-Q® Synthesis System (Millipore; 
Billerica, MA). The waveguides were allowed to dry for 30 minutes with optical heads 
facing down. Then the distal tip of each waveguide was coated with matte black ink, to 
provide a light dump for the 635nm laser beam, and was dried for two hours at 24ºC. One 
waveguide was glued into each of the four channels of the RAPTOR (Research 
International, Monroe, WA) coupon. The optical glue (Norland Products, Inc; Cranbury, 
NJ) was dried for 30 minutes using a long-wavelength ultraviolet lamp at 24ºC. Once the 
glue dried, the coupon was sealed in a small storage bag and stored at 24ºC for one to 
thirty days.  
Waveguide Preparation 
Twenty-four hours before a RAPTOR assay was performed 100 μl of HSA [100 
μg/ml] was added to two of the waveguides in a coupon, while the other two waveguides 
in the coupon were coated with 100 μl of streptavidin [100 μg/ml]. The treated 
waveguides were incubated for 18 hours at 4ºC, and then any excess protein was removed 
from the coupon by rinsing each waveguide three times with PBST. One hundred 
microliters of PG [50 μg/ml] was added to the HSA treated waveguides and allowed to 
incubate for 15 minutes at 24ºC. Any unbound PG was aspirated from the waveguides, 
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and fresh PG was added for a second 15 minute incubation. HSA-PG and streptavidin 
coated waveguides were rinsed three times with PBST. Goat polyclonal antibody raised 
against E. coli O157:H7 [50 μg/ml] was added to the HSA-PG treated waveguides; and 
goat polyclonal antibody raised against E. coli O157:H7 and biotin labeled [50 μg/ml] 
was added to streptavidin treated waveguides. Antibody solutions were incubated for 30 
minutes at 24ºC. Any unbound antibody was aspirated from the waveguides, and fresh 
antibody was added for a second 30 minute incubation. Each waveguide was rinsed three 
times with PBST. Once the waveguides in the coupon were treated with the appropriate 
capture matrix, the back side of the coupon was sealed with tape to prevent fluid leakage, 
and to maintain vacuum pressure inside the individual channels. To operate the biosensor, 
each RAPTOR assay was an automated function defined by a unique recipe, which was 
encoded by a certain number ranging from 0 to 63. The biosensor determined which 
recipe to follow based on a recipe card that was attached to the coupon, and marked with 
the appropriate recipe number. To avoid channel-related bias in the data, the position of 
the differently treated waveguides was alternated for each assay replicate. 
RAPTOR Assay Procedure 
The RAPTOR biosensor was assembled by connecting a piece of tubing to the 
buffer inlet and placing the other end in a container of PBST. Detector antibody, 1.0 ml, 
was placed in each of four reagent vials, and then tubing was used to connect the reagent 
vials with the reagent ports on the biosensor. A previously assembled coupon was placed 
securely into the biosensor, and the assay protocol was then commenced. A series of four 
blank samples consisting of 2.0 ml of PBS, injected into the sample port, were 
sequentially assayed to determine the background signal. The thirty-two minute assay 
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consisted of a 500 μl sample pulsed twelve times (40 μl of sample per pulse) over each of 
the four waveguides, with a two minute incubation period between pulses. The 
waveguides were then rinsed for 30 seconds with PBST. Two hundred microliters of 
detector antibody was pumped into each of the four waveguide channels and allowed to 
incubate for two minutes. After the incubation, the reagent pump was reversed to 
withdraw the detector antibody back into the reagent tubes. The waveguides were then 
rinsed twice for 30 seconds with PBST.  
Detection of the target was measured by fluorescence of the immune bound 
detector antibody, goat polyclonal antibody raised against E. coli O157:H7 and Cy5 or 
DyLight™649 labeled [5.0 μg/ml], for direct sandwich assays. After the baselines were 
determined, samples containing E. coli O157:H7 were interrogated by the capture matrix. 
Fluorescence emissions, within 100 - 1000 nm of the waveguide surface, were measured 
in picoamperes (pA) by a photodiode able to collect and quantitate emitted wavelengths 
above 650 nm.   
Blank samples were immediately followed by bacterial samples consisting of E. 
coli O157:H7 [1 x 102-7 CFU/ml], beginning with the lowest concentration, for limit of 
detection assays. Typically, three to four bacterial sample concentrations were tested per 
RAPTOR coupon. For capture efficiency assays, blank samples were immediately 
followed by one bacterial sample consisting of GFP-E. coli O157:H7 [1 x 106-8 CFU/ml]. 
Direct counts, using a Cellometer™ slide (Nexcelom Bioscience; Lawrence, MA), were 
used to determine sample concentrations (cells/ml) before the assays were performed. For 
data analysis, viable counts were performed on TSA or LB+AMP+ARA respectively, to 
determine sample concentrations (CFU/ml) retroactively. All RAPTOR data was 
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analyzed by Microsoft Excel. For capture efficiency experiments, assayed coupons were 
sealed in a plastic bag and stored at 4ºC for 24 to 72 hours until analyzed by fluorescent 
microscopy.  
Determination of Capture Efficiencies 
Cells captured on the waveguide were manually counted using a UIS2 LUCPlan 
FLM 20X long range objective mounted on an Olympus BX60 Epifluorescent 
microscope (Olympus America Inc.; Center Valley, PA). The optical head of each 
waveguide was carefully removed using a sterile razor blade. The waveguide was then 
secured to a clean glass slide using craft glue. After the glue dried (~2 minutes) 
photographs were taken using a SPOT Flex™ color CCD camera (Diagnostic 
Instruments Inc.;Sterling Heights, MI) and imaged using Adobe® Photoshop® Basic 
(Adobe Systems Inc; San Jose, CA). Cells were counted and averaged using three images 
per waveguide. Each viewable field represented 1 mm of waveguide length. Only 46 out 
of 360 degrees of the waveguide surface were viewable, so the average number of cells 
counted was multiplied by a correction factor (7.8 = 360º / 46º) to achieve the number of 
cells per mm of each waveguide. As depicted in Table 4, the number of cells counted per 
mm was multiplied by the length of the waveguide, 38mm, to produce the number of 
cells present on the surface of the entire waveguide. 
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= (Number of Cells on Three WGs / 3) * (360º/46º Viewable Angle) * Length of WG 
= Average Number of Cells per mm * 7.8 * 38 mm 
= Average Number of Cells per Waveguide 
 
Capture Efficiency = Average Number of Cells per Waveguide 
                            Sample Concentration (CFU/ml)  
 
 
TABLE 4. Capture Efficiency Calculations 
 
Detection of E. coli O157:H7 in Food Samples  
Ten grams of spinach or ground beef (20% fat) obtained from local grocers was 
placed in a Whirl-Pak® filter bag (Nasco; Fort Atkinson, WI) and inoculated with 1.0 ml 
of E. coli O157:H7 in PBS, and stored for 18 hours at 4°C. Fifty milliliters of buffered 
peptone water (BPW) was added to the filter bag, and then the samples were 
homogenized for thirty seconds using a Pulsifier (Microbiology International; Frederick, 
MD). The supernatant was removed and transferred to a 50 ml conical tube. Serial 
dilutions of the supernatant were prepared in BPW, and were used in the assay. The 
homogenized samples were assayed as described in the RAPTOR Assay Procedure 
section. 
Data Analysis 
Signal above the limit of detection (SALOD) values were calculated for each 
RAPTOR assay. The SALOD values were determined based on a method used to 
normalize the waveguides within each coupon. Each coupon contained four waveguides, 
and was considered an independent assay. Baselines were performed as described in the 
RAPTOR Assay Procedure section. Table 5 represents typical baseline values from a 
 24 
 
RAPTOR assay. The values in bold were the lowest value for each baseline. Typically, 
the same waveguide produced all four of the lowest baseline values for each assay. 
 
 Waveguide 1 Waveguide 2 Waveguide 3 Waveguide 4 
Baseline 1 672.7 584.7 576.1 402.8 
Baseline 2 703.4 594.4 617.9 433.6 
Baseline 3 731.0 612.9 641.7 465.5 
Baseline 4 763.8 623.1 675.8 489.6 
 
TABLE 5. Baseline Values 
 
The four waveguide values were divided by the bolded value to achieve a 
normalization coefficient, for each baseline. Table 8 shows the normalization coefficients 
for the baseline values from Table 5.  
 
 Waveguide 1 Waveguide 2 Waveguide 3 Waveguide 4 
Baseline 1 1.7 1.5 1.4 1.0 
Baseline 2 1.6 1.4 1.4 1.0 
Baseline 3 1.6 1.3 1.4 1.0 
Baseline 4 1.6 1.3 1.4 1.0 
 
TABLE 6. Normalization Coefficients 
 
The normalization coefficients, from Table 6, were used to normalize the baseline 
values from Table 5. For each waveguide, the baseline values from Table 5 were divided 
by the normalization coefficient for Baseline 4 in Table 6. Typically, the normalization 
coefficients did not vary between the third and fourth baseline. Table 7 shows the 
normalized baseline values.  
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 Waveguide 1 Waveguide 2 Waveguide 3 Waveguide 4 
Baseline 1 431.2 459.4 417.4 402.8 
Baseline 2 450.9 467.0 447.7 433.6 
Baseline 3 468.6 481.6 464.9 465.5 
Baseline 4 489.6 489.6 489.6 489.6 
 
TABLE 7. Normalized Baseline Values 
 
The normalized baselines, in Table 7, were evaluated for variability. For each 
waveguide, the four normalized baseline values were averaged and the standard deviation 
was calculated. A coefficient of variation (CoV) was determined by dividing the average 
normalized baseline value by the standard deviation. The CoV was then multiplied by 
100 to achieve a percentage. Data from any waveguide with a CoV percentage greater 
than ten was not used for data analysis or graph construction. Table 8 shows that all of 
the waveguides had baseline values with minimal variability. 
 
 Waveguide 1 Waveguide 2 Waveguide 3 Waveguide 4 
Average 460.1 474.4 454.9 447.9 
STDEV 24.9 13.7 30.4 37.8 
CoV (%) 5.4 2.9 6.7 8.4 
 
TABLE 8. Normalized Baseline Variability 
 
The limit of detection was determined to be the sum of the average normalized 
baseline plus three times the standard deviation, for each waveguide. Table 9 shows the 
level of detection for a typical RAPTOR assay.  
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 Waveguide 1 Waveguide 2 Waveguide 3 Waveguide 4 
LOD 534.8 515.4 546.0 561.3 
 
TABLE 9. Limit of Detection  
 
Once the LOD was calculated, the bacterial samples were assayed as described in 
the RAPTOR Assay Procedure section. Table 10 shows the sample values for a typical 
RAPTOR assay used to detect a series of E. coli O157:H7 concentrations. 
 
(CFU/ml) Waveguide 1 Waveguide 2 Waveguide 3 Waveguide 4 
1.4 x 102  796.0 637.5 721.2 519.8 
1.4 x 103  860.1 671.9 765.6 546.0 
1.4 x 104  1286.5 956.0 1050.0 782.6 
 
TABLE 10. Bacterial Sample Values 
 
The bacterial sample values were also normalized. For each waveguide, the 
values in Table 10 were divided by the normalization coefficients for Baseline 4 in Table 
6. Table 11 shows the bacterial sample values after normalization.  
 
 
(CFU/ml) Waveguide 1 Waveguide 2 Waveguide 3 Waveguide 4 
1.4 x 102  510.2 500.9 522.5 519.8 
1.4 x 103  551.3 527.9 554.7 546.0 
1.4 x 104  824.7 751.2 760.7 782.6 
 
TABLE 11. Normalized Bacterial Sample Values 
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The level of detection value from Table 9 was subtracted from the bacterial 
sample value in Table 10 to determine if the normalized bacterial sample value was 
positive or negative for the detection of E. coli O157:H7, for each waveguide.  
 
(CFU/ml) Waveguide 1 Waveguide 2 Waveguide 3 Waveguide 4 
1.4 x 102  -24.6 -14.5 -23.5 -41.5 
1.4 x 103  16.5 12.5 8.7 -15.3 
1.4 x 104  289.8 235.7 214.7 221.3 
 
TABLE 12. Final Detection Values  
 
Table 12 shows the finalized values for the detection of E. coli O157:H7 by the 
RAPTOR biosensor. A positive remainder was considered a positive detection of the 
target bacterium. A negative remainder indicated a negative detection of the target 
bacterium. For this example of a typical RAPTOR assay, the lowest concentration of E. 
coli O157:H7 detected was 1.4 x 103 CFU/ml for waveguides 1, 2 and 3; while 
waveguide 4 detected E. coli O157:H7 at 1.4 x 104 CFU/ml. 
Statistical Analysis 
A one-way ANOVA with Dunnett's post test was performed using GraphPad 
InStat 3.00 (San Diego, CA), for all RAPTOR assays. Paired data, in normal Gaussian 
distribution, was analyzed using a t test with a two tailed P value. Statistically significant 
P values (< 0.05) were noted on the graphs to aid in the analysis of the data. Raw data 
was analyzed using Microsoft Excel.     
 
     
  
 
RESULTS AND ANALYSIS 
Functional Albumin Binding Domain 
Indirect ELISAs were performed as described in the Materials and Methods 
section to verify the presence and functionality of the albumin binding domain in native 
PG, and a lack of albumin binding by recombinant PG.  
 
0.0 μg/ml 
HSA 
0.5 μg/ml 
HSA 
1.0  μg/ml 
HSA 
0.0 μg/ml 
HSA 
0.5 μg/ml 
HSA 
1.0  μg/ml 
HSA 
PG 0.0 μg/mL 1.0 1.0 1.0 1.0 1.0 1.0
PG 0.25 μg/mL 1.0 7.2 11.1 1.1 1.0 1.0
PG 0.5 μg/mL 1.1 10.1 14.7 1.0 0.9 0.9
PG 1 μg/mL 1.0 9.5 14.1 1.0 0.9 1.0
PG 2.5 μg/mL 1.0 10.0 14.3 1.0 0.9 0.9
PG 5 μg/mL 0.9 9.2 13.6 0.8 0.8 0.9
PG 10 μg/mL 1.1 9.4 12.6 0.9 0.8 0.9
PG 20 μg/mL 1.1 9.3 12.5 0.9 0.9 1.0
0
2
4
6
8
10
12
14
16
18
20
Si
gn
al
 to
 N
oi
se
 R
at
io
Native Protein G Recombinant Protein G
 
FIGURE 4. Verification of a Functional Albumin Binding Domain in Native PG Using 
ELISA Analysis. Rabbit polyclonal antibody [1.0 μg/ml], raised against goat 
immunoglobulin, was used as the primary antibody; while mouse monoclonal antibody 
[0.1 μg/ml], raised against rabbit immunoglobulin, and HRP labeled, was used as the 
secondary antibody. HSA (shown on graph) was used to immobilize PG (shown on 
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graph) before antibodies were added to the assay. Each column, and coinciding standard 
deviation bar, was calculated from the average of six data points; which were collected 
from three independent assays.    
 
A signal to noise ratio less than 2 was produced by all wells that contained 
recombinant PG (Figure 4). These low signals indicated the inability of recombinant PG 
to bind HSA. A signal to noise ratio greater than 2 was produced by all wells that 
contained native PG, which indicated that PG was bound to HSA. Native PG was 
implemented in all future assays for albumin binding.  
 
Alternative Albumin Species 
HSA was compared to other species of albumin to determine if it was the optimal 
species to immobilize PG in the capture matrix. Chicken ovalbumin (OVA) and bovine 
serum albumin (BSA) were tested as alternatives to HSA. Binding to PG, by OVA, BSA 
and HSA, was measured using indirect ELISAs as described in the Materials and 
Methods section. 
 
 1 µg/ml OVA 5 µg/ml OVA 1 µg/ml BSA 5 µg/ml BSA 1 µg/ml HSA 5 µg/ml HSA
0.25 µg/ml PG 1.1 1.0 1.2 1.5 9.9 13.2
0.5 µg/ml PG 1.1 1.1 1.2 1.9 11.4 14.7
1 µg/ml PG 1.3 1.2 1.3 2.5 12.3 16.3
2.5 µg/ml PG 1.2 1.2 1.6 3.2 12.4 17.1
5 µg/ml PG 1.2 1.3 1.9 3.9 12.4 16.8
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FIGURE 5. Verification of Specificity of Different Albumin Species for PG Using 
ELISA Analysis. Rabbit polyclonal antibody [1.0 μg/ml], raised against PG, was used as 
the primary antibody; while mouse monoclonal antibody [0.5 μg/ml], raised against 
rabbit immunoglobulin, and HRP labeled, was used as the secondary antibody. OVA, 
BSA, or HSA (shown on graph) was used to immobilize PG (shown on graph) before 
antibodies were added to the assay. Each column, and coinciding standard deviation bar, 
was calculated from the average of six data points; which were collected from three 
independent assays.    
 
A signal to noise ratio greater than 2 was produced only by wells that contained 
HSA at 1.0 and 5.0 μg/ml, and for BSA at 5.0 μg/ml (Figure 5). A signal to noise ratio 
less than 2 was produced by wells that contained OVA at 1.0 and 5.0 μg/ml, and for BSA 
at 1.0 μg/ml. The low signal to noise ratio produced from OVA indicated a lack of 
binding between PG and OVA. A high concentration of BSA was required to produce a 
signal to noise ratio greater than 2, when compared to HSA. These data indicated that 
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 BSA bound PG, but only at high BSA concentrations. A minimal concentration of HSA 
produced high signal to noise ratio (> 8). The signal to noise ratio for the lowest 
concentration of HSA-PG (9.9) was nearly three times the signal to noise ratio for the 
highest concentration of BSA-PG (3.9). These data indicated that the albumin binding 
domain of PG had greater affinity for HSA. These results indicated that HSA was the 
optimal albumin species for use in the alternative capture matrix. HSA was implemented 
as the albumin used to immobilize PG in all future assays.   
 
Optimal Ratio of HSA to PG 
 A direct sandwich ELISA was performed as described in the Materials and 
Methods section to determine the optimal ratio of HSA to PG for use in the capture 
matrix. E. coli O157:H7 was used to evaluate the capture of bacteria at the various 
concentrations of HSA and PG tested.   
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FIGURE 6. Verification of the Optimal Working Ratio of HSA to PG Using ELISA 
Analysis. Goat polyclonal antibody [1.0 μg/ml], raised against E. coli O157:H7, was used 
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as the primary antibody. Goat polyclonal antibody [1.0 μg/ml], raised against E. coli 
O157:H7 and HRP labeled, was used as the secondary antibody to detect captured E. coli 
O157:H7 at 8.1 x 107 CFU/ml. HSA (shown on graph) was used to immobilize PG 
(shown on graph) before antibodies were added to the assay. Each column, and 
coinciding standard deviation bar, was calculated from the average of two data points; 
which were collected from one assay. 
 
 A signal to noise ratio greater than 2 was produced by all wells that contained 
HSA and PG (Figure 6). The signal to noise ratio was greatest when the concentration of 
PG was 0.5 μg/ml and HSA was 1.0 μg/ml. The signal to noise ratio decreased as the 
concentration of both HSA and PG increased. These data suggested that the optimal 
working ratio of HSA to PG was 2:1. This ratio was implemented in all future assays. 
 
 The Role of HSA in the Alternative Capture Matrix 
 Indirect ELISAs were performed as described in the Materials and Methods 
section to clarify the role of HSA in the capture matrix. The immobilization of antibodies 
by PG alone, or in combination with HSA, was compared to determine the importance of 
HSA in the alternative capture matrix.  
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FIGURE 7. The Role of HSA in the Alternative Capture Matrix Clarified Using ELISA 
Analysis. Rabbit polyclonal antibody [1.0 μg/ml], raised against goat immunoglobulin, 
was used as the primary antibody; while mouse monoclonal antibody [0.1 μg/ml], raised 
against rabbit immunoglobulin and HRP labeled, was used as the secondary antibody. 
Each column, and coinciding standard deviation bar, was calculated from the average of 
six data points; which were collected from three independent assays.    
 
Minimal fluorescence was produced by wells that contained HSA alone (145.4 
pA) and PG alone (143.0 pA) (Figure 7). These data indicated that the primary or 
secondary antibodies did not bind to the HSA alone or PG alone. The greatest 
fluorescence was produced by wells that contained HSA and PG (1820.3 pA) in complex. 
The combination of HSA and PG significantly enhanced the fluorescence signal when 
compared to HSA alone and PG alone. The primary and secondary antibodies used in the 
assay were not specific for PG. However, these nonspecific antibodies produced the 
greatest fluorescence (1820.3 pA) when used to label PG, which was immobilized by 
HSA. This suggested that the PG Fc binding domain bound to the Fc domain of at least 
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 one of the antibodies used.  As indicated by these data, an enhanced ability to immobilize 
antibodies existed when PG was oriented on a HSA coated surface.  
 
The Role of HSA in Capturing Bacteria 
Direct sandwich ELISAs were performed as described in the Materials and 
Methods section to clarify the role of HSA in the capture of bacteria. E. coli O157:H7 
was used to show the capture of bacteria by HSA, PG or a combination of HSA and PG.   
 
172.1
361.5
2897.1
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
1 µg/ml HSA 1 µg/ml PG 1 µg/ml HSA and 1 µg/ml PG 
R
aw
 F
lu
or
es
ce
nc
e 
(p
A
) ---------- P < 0.0001 -----------
---------- P < 0.0001 -----------
FIGURE 8. The Role of HSA in Capturing Bacteria Clarified Using ELISA Analysis. 
Goat polyclonal antibody [1.0 μg/ml], raised against E. coli O157:H7, was used as the 
capture antibody and primary detector antibody. Mouse monoclonal antibody [0.1 μg/ml], 
raised against goat immunoglobulin and HRP labeled, was used as the secondary detector 
antibody to detect captured E. coli O157:H7 at 4.7 x 106 CFU/ml. Each column, and 
coinciding standard deviation bar, was calculated from the average of six data points; 
which were collected from three independent assays.   
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Minimal fluorescence (172.1 pA) was produced by wells that contained HSA 
alone, which indicated that bacteria was not captured by HSA (Figure 11). Significantly 
(P < 0.05) elevated fluorescence was produced by wells that contained PG alone (361.5 
pA). The increased fluorescence by PG alone was minor, compared to the fluorescence 
produced by wells that contained the HSA and PG complex (2897.1 pA). PG, in 
combination with HSA, was able capture bacteria significantly (P < 0.05) better than 
HSA or PG alone. The HSA-PG combination was implemented in all future assays.   
 
Species Specificity of the Fc Binding Domain  
The species specificity of the PG Fc binding domain was explored using 
competitive ELISAs as described in the Materials and Methods section. One species of 
antibody, labeled with HRP, was forced to compete for the Fc binding domain on PG 
with an equal concentration of unlabelled antibody from another species. This 
competition was performed to demonstrate the strong affinity of the PG Fc binding 
domain for goat antibodies, and a lesser affinity for mouse antibodies, which had been 
shown in previous research (1, 4, 14,).  
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FIGURE 9. Verification of Species Specificity for the Fc Binding Domain of PG Using 
ELISA Analysis. Goat polyclonal antibody [1.0 μg/ml], raised against E. coli O157:H7 
and unlabeled, or raised against rabbit immunoglobulin and HRP labeled, was used to 
compete with mouse monoclonal antibodies for the Fc binding domain of PG [1.0 μg/ml], 
raised against rabbit immunoglobulin and HRP labeled, or raised against E. coli O157:H7 
and unlabeled. HSA [1.0 μg/ml] was used to immobilize PG before the antibodies were 
added. Each column, and coinciding standard deviation bar, was calculated from the 
average of six data points; which were collected from three independent assays.    
 
Signal to noise ratios greater than 2 were produced by all wells that contained PG 
and HRP labeled goat polyclonal antibody raised against rabbit immunoglobulin, with 
unlabeled mouse monoclonal antibody raised against E. coli O157:H7. This data 
indicated that the goat species antibody was the stronger competitor for the Fc binding 
domain of PG (Figure 9). Signal to noise ratios less than 2 were produced by all wells 
that contained HRP labeled mouse monoclonal antibody raised against rabbit 
immunoglobulin, with unlabeled goat polyclonal antibody raised against E. coli 
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 O157:H7. This data indicated that the Fc binding domain of PG had minimal affinity for 
the mouse species antibody. These data corroborated the strong affinity of PG Fc binding 
domain for the goat antibodies, and the weak binding of mouse antibodies to PG, as 
stated in previous studies (1, 4, 14).  
 
Optimal Capture Antibody Species 
The abilities of rabbit and goat polyclonal antibodies to bind to the Fc binding 
domain on PG were compared to determine the optimal species of capture antibody for 
use in the alternative capture matrix. Indirect ELISAs were performed as described in the 
Materials and Methods section. 
 
1.0 1.0 1.01.0 1.0 1.01.0
3.1
6.7
1.2
4.7
8.0
0
2
4
6
8
10
12
14
16
18
20
0.0 0.5 1.0
Si
gn
al
 to
 N
oi
se
 R
at
io
Human Serum Albumin (μg/ml)
0.0 PG μg/ml
0.0 PG μg/ml
0.5 PG μg/ml
0.5 PG μg/ml
--P < 0.01--
--P < 0.05--
 
FIGURE 10. Determination of the Optimal Capture Antibody Species Using ELISA 
Analysis. Goat polyclonal antibody (       /      ), raised against E. coli O157:H7, or rabbit 
polyclonal antibody (      /     )   raised against goat immunoglobulin, were used as 
primary antibodies [1.0 μg/ml]. Mouse monoclonal antibodies raised against goat or 
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rabbit immunoglobulin, and HRP labeled, were used as the secondary antibodies [0.1 
μg/ml], respectively. HSA (shown on graph) was used to immobilize PG (shown on 
graph) before antibodies were added to the assay. Each column, and coinciding standard 
deviation bar, was calculated from the average of six data points; which were collected 
from three independent assays.    
 
Signal to noise ratios greater than 2 were produced by all wells that contained PG 
and HSA. These data indicated that rabbit and goat polyclonal antibodies bound to the Fc 
binding domain of PG in the alternative capture matrix (Figure 10). Goat polyclonal 
antibody raised against E. coli O157:H7 produced significantly (P < 0.05) higher signal 
to noise ratios when compared to rabbit polyclonal antibody raised against goat 
immunoglobulin. These data suggested that goat species antibody was the most effective 
capture antibody in the alternative capture matrix, when compared to rabbit species 
antibody. The rabbit species antibody bound to the Fc binding domain of PG, which 
suggested that it may be effective as a capture antibody if goat species antibody was not 
readily available for a particular target. Goat polyclonal antibody raised against E. coli 
O157:H7 was implemented as the capture antibody in further assays. 
 
Optimal Concentration of Detector Antibody  
Direct sandwich ELISAs were performed as described in the Materials and 
Methods section. Goat polyclonal antibody, raised against E. coli O157:H7 and HRP 
labeled, was used to determine the optimal concentration of detector antibody for the 
alternative capture matrix.  
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FIGURE 11. Determination of the Optimal Concentration of Detector Antibody Using 
ELISA Analysis. Goat polyclonal antibody [1.0 μg/ml], raised against E. coli O157:H7, 
was used as the capture antibody.  Goat polyclonal antibody [1.0, 2.5, 5.0 μg/ml], raised 
against E. coli O157:H7 and HRP labeled, was used as the detector antibody to detect 
captured E. coli O157:H7 (CFU/ml shown on graph). E. coli K-12 [1.5 x 107 CFU/ml] 
was used as a negative control. HSA [1.0 μg/ml] was used to immobilize PG [0.5 μg/ml] 
before antibodies were added to the assay. Each column, and coinciding standard 
deviation bar, was calculated from the average of six data points; which were collected 
from three independent assays.    
 
Signal to noise ratios greater than 2 were produced by all wells that contained E. 
coli O157:H7 at 3.0 x 106 through 3.0 x 108 CFU/ml (Figure 11). Signal to noise ratios 
decreased when the concentration of detector antibody increased. These data suggested 
that saturation of PG began at, or before, 1.0 μg/ml of detector antibody. Based on the 
greatest signal to noise ratio, the optimal concentration of detector antibody was 1.0 
μg/ml or less.  
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 Capture Antibody Displacement 
 Direct sandwich ELISAs were performed as described in the Materials and 
Methods section. The absence of E. coli O157:H7 was used to determine if the detector 
antibody, goat polyclonal antibody raised against E. coli O157:H7 and HRP labeled, had 
displaced the capture antibody, goat polyclonal antibody raised against E. coli O157:H7, 
for the Fc binding domain on PG.  
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FIGURE 12. Capture Antibody Displacement Evaluated Using ELISA Analysis. Goat 
polyclonal antibody [1.0 μg/ml], raised against E. coli O157:H7, was used as the capture 
antibody. Goat polyclonal antibody [0.1, 0.5 or 1.0 μg/ml], raised against E. coli 
O157:H7 and HRP labeled, was used as the detector antibody, to detect captured E. coli 
O157:H7 [9.7 x 106 CFU/ml]. The absence of bacteria was used as the negative control. 
HSA [1.0 μg/ml] was used to immobilize PG [0.5 μg/ml] before antibodies were added to 
the assay. Each column, and coinciding standard deviation bar, was calculated from the 
average of six data points; which were collected from three independent assays.    
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Fluorescence above 2000 pA was produced by all wells that contained E. coli 
O157:H7 (Figure 12). These data indicated that the alternative capture matrix captured 
 the targeted cells. In the presence of bacteria, fluorescence signals were not increased 
significantly (P < 0.05) when the concentration of detector antibody was increased. This 
lack of signal increase suggested that the antigen binding sites were saturated by detector 
antibody at 0.5 μg/ml. Minimal fluorescence (< 700 pA) was produced by all wells that 
lacked bacteria. These data indicated that the detector antibody, at 0.5 and 1.0 μg/ml, did 
not bind to PG. This lack of binding suggested that the detector antibody did not displace 
the capture antibody from the Fc binding domain of PG. Goat polyclonal antibody raised 
against E. coli O157:H7 and HRP labeled was implemented as the detector antibody in 
all future ELISAs.    
 
Limit of Detection for Two Capture Matrices Using ELISA Analysis 
Direct sandwich ELISAs were performed as described in the Materials and 
Methods section. The streptavidin-biotin and HSA-PG capture matrices were compared 
to determine the limit of detection for E. coli O157:H7.  
 
0.8 0.7 0.8
2.4
15.4
20.4 19.4
0.8 0.8 0.9
4.0
21.5
26.3 23.4
0
5
10
15
20
25
30
35
Si
gn
al
 to
 N
oi
se
 R
at
io
E. coli (CFU/ml) 
Streptavidin-Biotin-IgG
HSA-Protein G-IgG
-P < 0.05-
-P < 0.05-
-P < 0.005-
-P < 0.05-
FIGURE 13. Determination of the Limit of Detection for Two Capture Matrices Using 
ELISA Analysis. Goat polyclonal antibodies [1.0 μg/ml], raised against E. coli O157:H7 
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and unlabeled or biotinylated, were used as the capture antibody. Goat polyclonal 
antibody [1.0 μg/ml], raised against E. coli O157:H7 and HRP labeled, was used as the 
detector antibody, to detect captured E. coli O157:H7 (CFU/ml shown on graph). E. coli 
K-12 (CFU/ml shown on graph) was used as the negative control. HSA [1.0 μg/ml] was 
used to immobilize PG [0.5 μg/ml], before antibodies were added to the HSA-PG matrix. 
Streptavidin [1.0 μg/ml] was used to immobilize the biotinylated capture antibody, before 
bacteria were added to the assay. Each column, and coinciding standard deviation bar, 
was calculated from the average of six data points; which were collected from three 
independent assays.    
 
Signal to noise ratios less than 2 were produced by all wells that contained the 
negative control, E. coli K-12. These data indicated that E. coli K-12 was not detected by 
either capture matrix. Signal to noise ratios greater than 2 were produced by all wells that 
contained E. coli O157:H7, from 9.7 x 104 through 1 x 107 CFU/ml. This high signal to 
noise ratio indicated that the limit of detection for E. coli O157:H7 was 9.7 x 104 CFU/ml 
for both capture matrices using ELISA analysis. The HSA-PG capture matrix produced 
signal to noise ratios that were significantly higher than the streptavidin-biotin capture 
matrix, at every concentration of E. coli O157:H7. These data suggested that the HSA-PG 
capture matrix was a better method for the capture of target bacterial cells using ELISA 
analysis.    
 
 
 
 The Limit of Detection of Two Capture Matrices Using RAPTOR 
 RAPTOR assays, using a sandwich assay format, were performed as described in 
the Materials and Methods section. Experiments were conducted to compare the detection 
limit of the streptavidin-biotin-IgG capture matrix to the HSA-PG-IgG capture matrix. 
GFP-E. coli O157:H7 was used to show the capture of bacteria by these matrices.    
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FIGURE 14. Determination of the Limit of Detection for Two Capture Matrices Using 
RAPTOR Analysis. Goat polyclonal antibodies [50.0 μg/ml], raised against E. coli 
O157:H7 and unlabeled or biotinylated, were used as the capture antibody. Goat 
polyclonal antibody [5.0 μg/ml], raised against E. coli O157:H7 and Cy5 labeled, was 
used as the detector antibody, to detect captured GFP-E. coli O157:H7 (CFU/ml shown 
on graph). HSA [100.0 μg/ml] was used to immobilize PG [50.0 μg/ml], before 
antibodies were added to the HSA-PG matrix. Streptavidin [100.0 μg/ml] was used to 
immobilize the biotinylated capture antibody, before bacteria were added to the assay. 
Each column, and coinciding standard deviation bar, was calculated from the average of 
two data points from 1.0 x 105 and 1.0 x 106 CFU/ml, six data points from 1.4 x 104 
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CFU/ml, and eight data points from 1.9 x 102 and 1.9 x 103 CFU/ml; which were 
collected from five independent assays.    
 
 Positive SALOD values were produced by waveguides used to assay 1.9 x 103 
through 1.3 x 106 CFU/ml of GFP-E. coli O157:H7 (Figure 14). These data indicated that 
the limit of detection for both matrices was 1.9 x 103 CFU/ml. No significant difference 
was observed between the two matrices at 1.9 x 102 through 1.4 x 104 CFU/ml of GFP-E. 
coli O157:H7. These data indicated that both matrices captured the target bacteria for 
detection below 1.0 x 105 CFU/ml, and produced similar SALOD values. The HSA-PG 
capture matrix produced significantly (P < 0.05) greater SALOD values at 1.0 x 105 
through 1.3 x 106 CFU/ml; when compared to the streptavidin-biotin capture matrix. 
These data suggested that the HSA-PG capture matrix was the better method for capture 
of target bacterial cells at high concentrations using the RAPTOR.  
 
The Limit of Detection for Ground Beef Homogenate Supernatant 
RAPTOR assays, using a sandwich format with direct detection, were performed 
as described in the Materials and Methods section. Ground beef homogenate supernatant 
fluid, containing E. coli O157:H7, was used to compare the HSA-PG and streptavidin-
biotin capture matrices for use in an animal-based food sample.   
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FIGURE 15. Determination of the Limit of Detection for Two Capture Matrices in 
Homogenized Ground Beef Supernatant Fluid Using RAPTOR Analysis. Goat polyclonal 
antibodies [50.0 μg/ml], raised against E. coli O157:H7 and unlabeled, or biotinylated, 
was used as the capture antibody. Goat polyclonal antibody [5.0 μg/ml], raised against E. 
coli O157:H7 and Cy5 labeled, was used as the detector antibody, to detect captured E. 
coli O157:H7 (CFU/ml shown on graph). HSA [100.0 μg/ml] was used to immobilize PG 
[50.0 μg/ml], before antibodies were added to the HSA-PG matrix. Streptavidin [100.0 
μg/ml] was used to immobilize the biotinylated capture antibody before bacteria were 
added to the assay. Each column, and coinciding standard deviation bar for the HSA-PG 
capture matrix, was calculated from the average of two data points for 7.0 x 104 CFU/ml, 
seven data points from 5.4 x 105 and 5.4 x 106 CFU/ml, and three data points for 3.8 x 107 
CFU/ml; which were collected from three independent assays. Each column, and 
coinciding standard deviation bar for the streptavidin-biotin capture matrix, was 
calculated from the average of three data points; which were collected from three 
independent assays. The streptavidin-biotin capture matrix was not tested at the 7.0 x 104 
CFU/ml sample concentration. 
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 Positive SALOD values were produced by all waveguides treated with the HSA-
PG and 5.4 x 105 CFU/ml of E. coli O157:H7 (Figure 15). All waveguides treated with 
streptavidin-biotin produced positive SALOD values at 5.4 x 106 CFU/ml of E. coli 
O157:H7; which was one log less sensitive when compared to the HSA-PG capture 
matrix. For each bacterial concentration, SALOD values were not significantly (P > 0.05) 
greater for the HSA-PG capture matrix, when compared to the streptavidin-biotin capture 
matrix. These data indicated that the HSA-PG capture matrix was the better method used 
to capture target bacteria in beef homogenized supernatant fluid, using the RAPTOR for 
detection.   
 
The Limit of Detection for Spinach Leaf Homogenate Supernatant 
RAPTOR assays, using a sandwich format with direct detection, were performed 
as described in the Materials and Methods section. Spinach leaf homogenate supernatant 
fluid containing E. coli O157:H7, was used to test the HSA-PG capture matrix in a plant-
based food sample.   
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FIGURE 16. Determination of the Limit of Detection for the HSA-PG Capture Matrix in 
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Homogenized Spinach Leaf Supernatant Fluid Using RAPTOR Analysis. Goat 
polyclonal antibodies [50.0 μg/ml], raised against E. coli O157:H7 and unlabeled, was 
used as the capture antibody. Goat polyclonal antibody [5.0 μg/ml], raised against E. coli 
O157:H7 and Cy5 labeled, was used as the detector antibody, to detect captured E. coli 
O157:H7 (CFU/ml shown on graph). HSA [100.0 μg/ml] was used to immobilize PG 
[50.0 μg/ml], before antibodies were added to the HSA-PG matrix. Each column, and 
coinciding standard deviation bar, was calculated from the average of four data points; 
which were collected from one assay. 
 
 Positive SALOD values were produced for 2.9 x 105 CFU/ml E. coli O157:H7 
(Figure 16). These data suggested that the limit of detection of E. coli O157:H7 in 
spinach homogenate supernatant fluid was 2.9 x 105 CFU/ml (Figure 16). SALOD values 
increased more than two logs when the bacterial concentration was increased by one log, 
to 2.9 x 106 CFU/ml. This unusual increase in signal suggested that the fluorescence 
detected may have been influenced by a component in the spinach homogenate 
supernatant fluid. These data suggested that the SALOD values obtained were not 
accurately interpreted by the RAPTOR assay.       
 
The Capture Efficiency for Two Capture Matrices on Waveguide Surfaces 
The capture efficiency of the HSA-PG capture matrix was compared to the 
capture efficiency of the streptavidin-biotin capture matrix using GFP-E. coli O157:H7. 
RAPTOR assays were performed using a direct sandwich assay format as described in 
the Materials and Methods section. After the RAPTOR assays were performed, the 
 amount of bacterial cells captured on the surfaces of the waveguides was measured using 
fluorescent microscopy, as described in the Materials and Methods section. 
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FIGURE 17. Average Numbers of Cells Captured on the Waveguide Surface After 
RAPTOR Analysis. Goat polyclonal antibodies [50.0 μg/ml], raised against E. coli 
O157:H7 and unlabeled or biotinylated, were used as the capture antibody. Goat 
polyclonal antibody [5.0 μg/ml], raised against E. coli O157:H7 and Cy5 labeled, was 
used as the detector antibody, to detect captured GFP-E. coli O157:H7 (CFU/ml shown 
on graph). HSA [100.0 μg/ml] was used to immobilize PG [50.0 μg/ml], before 
antibodies were added to the HSA-PG matrix. Streptavidin [100.0 μg/ml] was used to 
immobilize the biotinylated capture antibody before bacteria were added to the assay. 
Each column, and coinciding standard deviation bar, was calculated from the average of 
six data points for 3.7 x 106 CFU/ml, four data points for 5.3 x 107 CFU/ml; which were 
collected from six independent assays. Each column, and coinciding standard deviation 
bar, was calculated from the average of three data points for 1.7 x 108 CFU/ml using the 
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 HSA-PG matrix and one data point for 1.7 x 108 CFU/ml using the streptavidin biotin 
matrix; which were collected from three independent assays.  
 
The average number of cells manually counted in each viewable field on the 
surface of waveguides ranged from seven for sample concentrations of 3.7 x 106 CFU/ml, 
to over four hundred for sample concentrations of 1.7 x 108 CFU/ml. Waveguides treated 
with the HSA-PG capture matrix retained twice the amount of cells, when compared to 
the streptavidin-biotin capture matrix, at 3.7 x 106 CFU/ml; which was a significantly (P 
< 0.05) greater amount (Figure 17). Waveguides treated with the HSA-PG capture matrix 
failed to significantly improve the amount of cells captured on the waveguide surface, 
when compared to waveguides treated with the streptavidin-biotin capture matrix from 
5.3 x 107 through 1.7 x 108 CFU/ml. 
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FIGURE 18. Average Capture Efficiency on the Waveguide Surface After RAPTOR 
Analysis. Goat polyclonal antibodies [50.0 μg/ml], raised against E. coli O157:H7 and 
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unlabeled or biotinylated, were used as the capture antibody. Goat polyclonal antibody 
[5.0 μg/ml], raised against E. coli O157:H7 and Cy5 labeled, was used as the detector 
antibody, to detect captured GFP-E. coli O157:H7 (CFU/ml shown on graph). HSA 
[100.0 μg/ml] was used to immobilize PG [50.0 μg/ml], before antibodies were added to 
the HSA-PG matrix. Streptavidin [100.0 μg/ml] was used to immobilize the biotinylated 
capture antibody before bacteria were added to the assay. Each column, and coinciding 
standard deviation bar, was calculated from the average of six data points for 3.7 x 106 
CFU/ml, four data points for 5.3 x 107 CFU/ml; which were collected from six 
independent assays. Each column, and coinciding standard deviation bar, was calculated 
from the average of three data points for 1.7 x 108 CFU/ml using the HSA-PG matrix and 
one data point for 1.7 x 108 CFU/ml using the streptavidin biotin matrix; which were 
collected from three independent assays.  
 
The capture efficiency (%) was greatest at 3.7 x 106 CFU/ml, and decreased as the 
sample concentration increased, for both capture matrices. The HSA-PG capture matrix 
showed significantly (P < 0.05) greater capture efficiency when compared to streptavidin-
biotin for 3.7 x 106 CFU/ml. At sample concentrations from 5.3 x 107 through 1.7 x 108 
CFU/ml, the waveguides treated with the HSA-PG capture matrix failed to significantly 
increase the capture efficiencies of GFP-E. coli O157:H7 on waveguide surfaces, when 
compared to waveguides treated with the streptavidin-biotin matrix. 
 
 
 
 A Comparison of DyLight™649 and Cy5 Labeled Detector Antibody 
Attainment of a lower limit of detection for the HSA-PG capture matrix was 
attempted by testing an alternative detection fluorophore. The DyLight™649 fluorophore 
has been reported by the manufacturer as being more photo stable than the Cy5 
fluorophore. RAPTOR assays were performed, using a direct sandwich format, as 
described in the Materials and Methods section, to compare detection limits of Cy5, and 
DyLight™649 labeled detector antibodies. GFP-E. coli O157:H7 was used to show the 
detection of bacteria using waveguides treated with the HSA-PG capture matrix. 
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FIGURE 19. A Comparison of DyLight™649 and Cy5 Labeled Detector Antibody Using 
RAPTOR Analysis. Goat polyclonal antibodies [50.0 μg/ml], raised against E. coli 
O157:H7 and unlabeled, was used as the capture antibody. Goat polyclonal antibodies 
[5.0 μg/ml], raised against E. coli O157:H7 and DyLight™649 or Cy5 labeled, was used 
as the detector antibody, to detect captured GFP-E. coli O157:H7 (CFU/ml shown on 
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graph). HSA [100.0 μg/ml] was used to immobilize PG [50.0 μg/ml], before antibodies 
were added to the HSA-PG matrix. Each column, and coinciding standard deviation bar, 
was calculated from the average of three data points; which were collected from two 
independent assays. 
 
A significant (P > 0.05) difference was not found between the SALOD values 
produced from DyLight™649 and Cy5 labeled detector antibodies, for all sample 
concentrations tested (Figure 19). The limit of detection was the same for 6.0 x 103 
CFU/ml, for both fluorophores tested. These data suggested that the use of DyLight™649 
labeled detector antibodies failed to increase the sensitivity of the RAPTOR assay, when 
compared to the use of Cy5 labeled detector antibodies, to detect E. coli O157:H7. 
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DISCUSSION 
An alternative method for immobilizing capture antibody on an immunoassay 
surface was explored, after existing strategies were researched (5, 6, 11, 15, 16, 19, 22, 
23, 24, 31, 34, 35, 39, 40). One common strategy for securing capture antibodies to a 
polystyrene surface is to passively adsorb streptavidin to the surface. The streptavidin 
coated surface is then used to bind biotinylated capture antibodies. This binding is 
incredibly strong (13), and resists denaturation of the immobilized antibody (39), which 
led to a broad acceptance for this method (6, 19, 23, 36) in the field of microbiology and 
immunology. Biotinylation of the antibody is done by a covalent interaction targeted 
towards primary amines, which are located on the constant and variable regions of the 
antibody heavy chain. When the biotinylated antibody is incubated on the streptavidin 
coated surface the immobilization results in a random orientation of the antibodies (24, 
31). This lack of uniformity, of the biotinylated antibody may cause poor sensitivity (3, 
24), which currently plagues immunoassays (6, 19, 23, 36). To test this reasoning, an 
alternative capture matrix was constructed and then compared to the streptavidin-biotin 
matrix.  
The most abundant form of streptococcal PG, available on the commercial 
market, is a recombinant PG, which lacks an albumin binding domain (14 kDa); which is 
located near the amine terminus. Recombinant PG is commonly employed to remove 
antibodies from serum without nonspecifically binding to the albumin present. This 
common use of the recombinant form of PG led to a minimal demand for the native form 
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of PG. For this research, obtaining native PG with an intact and functional albumin 
binding domain was essential. This native form of PG has limited commercial 
availability; and only one company, Calbiochem, was located that sold the native protein, 
with the intact albumin binding domain. Validation of the presence and functionality of 
the albumin binding domain in this product was the first step performed to construct the 
alternative capture matrix. In the presence of HSA, Figure 4 shows the functionality of 
the albumin binding domain in native PG, by the production of signal to noise ratios 
greater than the signal to noise ratios produced by recombinant PG. These results 
indicated that native PG had a functional albumin binding domain able to bind HSA. 
These results also indicated that recombinant PG did not have a functional albumin 
binding domain, and was not able to bind to HSA. The use of native PG was 
implemented for all future assays.  
Different species of albumin were tested to determine the species specificity of 
the albumin binding domain of PG. The albumin species tested were chosen based on a 
previous study (25); which showed that human, rabbit and bovine serum inhibited the Fc 
binding of radiolabeled human species antibodies to bacterial cells from group G and C 
streptococci. This binding inhibition suggested that the radiolabeled antibodies were 
displaced by competitive antibodies present in the serum. This inhibition did not occur 
when chicken, rat, dog and cat serum were tested (25). The Fc binding domain of PG was 
shown to bind to rabbit and human species antibody (4), but did not bind to chicken 
species antibody (14). This pattern of species specificity demonstrated by the Fc binding 
domain led to the reasoning that the specificity may be transferrable to the albumin 
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binding domain. To test this theory, PG was immobilized by human serum albumin 
(HSA), bovine serum albumin (BSA), or chicken ovalbumin (OVA). 
Minimal signal to noise ratios were produced by wells that contained OVA, which 
indicated that OVA did not immobilize PG (Figure 5). Signal to noise ratios greater than 
two were produced by wells that contained 5.0 μg/ml of BSA, which indicated that high 
concentrations of BSA did immobilize PG. Interaction between BSA and PG was 
important to consider because many laboratory reagents, such as antibodies, contain 
nominal concentrations of BSA as a stabilizing agent. These results indicated that small 
amounts of BSA in the reagents did not interfere with the assays using the HSA-PG 
capture matrix. HSA showed the greatest binding to PG, even at minimal concentrations, 
which indicated that human was the optimal species of albumin for use in the alternative 
capture matrix. As theorized, the species specificity shown by the Fc binding domain was 
also shared by the albumin binding domain. Further studies, using rabbit, goat, and 
mouse sera, are needed to explore the relationship between species specific domains on 
multi-functional proteins, and to find a superior albumin species to immobilize PG, to 
assay surfaces.  
A range of concentrations of PG and HSA were tested to determine the optimal 
working ratio of these two components in the alternative capture matrix. Figures 4 and 5 
compare the concentrations of HSA and PG without the presence of bacteria. Based on 
the greatest signal to noise ratios, Figure 4 shows the optimal concentration of HSA was 
1.0 μg/ml, and PG was 0.5 μg/ml. Figure 5 shows the greatest signal to noise ratios at 5.0 
μg/ml for HSA, and 2.5 μg/ml for PG. Higher concentrations showed greater signal to 
noise ratios, but the ratio of the components was identical, at 2.0 μg/ml of HSA for every 
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1.0 μg/ml PG. E. coli O157:H7 was added to the experiment to verify that this ratio was 
optimal in the presence of bacteria and to better anticipate the activity of these 
components during a working immunoassay. Figure 6 shows the signal to noise ratios for 
1.0 μg/ml of HSA and 0.5 μg/ml of PG. The 2:1 ratio produced the greatest signal to 
noise ratios, using the lower concentrations of HSA and PG to capture E. coli O157:H7. 
This 2:1 ratio of HSA and PG was implemented for all future assays. 
In previous studies, fragments of PG or intact PG, have been used to immobilize 
capture antibodies on assay surfaces in immunoassays (3, 18, 40). Methods to secure PG 
to the assay surface, e.g., amine or thiol reactive chemistry (3, 40), have improved 
antibody activity, when compared to direct adsorption. Covalent attachment of the 
albumin binding domain of PG to Fab fragments has further improved antibody activity, 
by immobilizing the antibody on a HSA coated surface (18). In this study, the role of 
HSA in the alternative capture matrix was clarified by comparing antibody 
immobilization using HSA, PG or HSA-PG combined.  
Figure 7 shows antibodies immobilized by HSA alone, PG alone, and PG and 
HSA combined, in the absence of bacteria. Minimal fluorescence was produced by HSA 
alone and PG alone which indicated that the antibodies were not immobilized. The 
combination of HSA and PG produced the greatest fluorescence, which was significantly 
(P < 0.05) greater than the fluorescence produced by PG alone or HSA alone. The 
antibodies used were not specific for HSA or PG so any binding was via the Fc domain, 
which constituted non-immune binding; and not via the antibody paratopes, which are 
used for immune binding. This improved fluorescence indicated that a greater amount of 
primary antibody was immobilized by PG when PG was immobilized by HSA. As shown 
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in a previous study, the greater density of immobilized antibody contributed to greater 
sensitivity of the assay when a target was introduced (24). E. coli O157:H7 was 
introduced into the experiment to test this theory using the alternative capture matrix.  
Figure 8 shows minimal fluorescence produced by HSA alone, which indicated 
that E. coli O157:H7 was not captured by HSA alone. Significantly greater fluorescence 
was produced by PG alone, which suggested that PG immobilized capture antibody and 
bacteria for detection. The greatest fluorescence was produced by HSA and PG 
combined, when compared to fluorescence produced by PG or HSA alone. When PG was 
immobilized by an albumin coated surface, the Fc binding domain was available to bind 
antibodies in the environment. Previous study has shown that the structure of PG consists 
of structurally opposite Fc and albumin binding domains. PG was able to bind an 
antibody molecule and an albumin molecule at the same time, without allosteric 
modulation (7). This strict orientation of antibody, by the Fc binding domain, allowed for 
a greater incidence of antibody binding, when compared to PG passively adsorbed to a 
non-albumin coated surface; which resulted in random orientation of the PG (27). The 
greater availability of the Fc binding domain was characterized by a greater density of 
capture antibody; which resulted in the enhanced capture of E. coli O157:H7. The use of 
PG immobilized by HSA was implemented for all future assays.  
The optimal species of antibody for use as capture and detector antibody was 
determined for use in the alternative capture matrix. Figure 9 and 10 show the results of a 
series of competitive ELISAs used to investigate the species specificity of the Fc binding 
domain of PG. In Figure 9, competitive ELISAs were used to compare goat and mouse 
antibodies. Signal to noise ratios greater than 6 were produced by all wells that contained 
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HRP labeled goat antibodies, and unlabeled mouse antibodies. These results indicated 
that the goat antibodies were stronger competitors for the Fc binding domain of native 
PG. The success of goat antibody in competing for the Fc binding domain of PG 
suggested that goat species antibody was a prime candidate for use as the capture 
antibody in the alternative capture matrix. Signal to noise ratios less than 2 were 
produced by all wells that contained HRP labeled mouse antibodies and unlabeled goat 
antibodies. These results indicated that the HRP labeled mouse antibody failed to 
compete for Fc binding domain of PG. This failure suggested that mouse species 
antibody should not be implemented as a capture antibody in the alternative capture 
matrix. A previous study reported similar findings as shown in Table 2 (14). Nearly five 
times the amount of mouse polyclonal antibody (1020 ng) was required to produce fifty 
percent inhibition of binding between the Fc binding domain of PG and rabbit polyclonal 
antibody, when compared to only 217 ng of goat polyclonal antibody, required to 
produce the same inhibition. The greater requirement for mouse antibody, compared to 
goat antibody, suggested that the Fc binding domain of PG had greater affinity for goat 
species antibody (14). These results led to the potential use of mouse antibody as a 
detector antibody; while goat species antibody was implemented as the capture antibody 
in the developing capture matrix. 
Further species specificity analysis of the Fc binding domain was warranted to 
investigate alternative capture antibodies for use in the alternative capture matrix. Table 2 
shows the similar affinity of PG for rabbit and goat species antibody. Polyclonal goat and 
rabbit antibodies were compared using indirect ELISAs. To avoid competitive binding to 
PG, indirect detection was performed by HRP labeled mouse antibodies, which were 
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raised against goat or rabbit antibodies. Figure 10 shows signal to noise ratios that were 
significantly (P < 0.05) greater for wells that contained goat antibodies, when compared 
to wells that contained rabbit antibody. These results suggested that goat species antibody 
was the preferred candidate for use as a capture antibody. Rabbit antibodies showed the 
second highest affinity for the Fc binding domain of PG, and could therefore potentially 
be employed as an alternative capture antibody in the event that a goat species antibody is 
not readily available for a particular antigen. Since PG showed high affinity for the goat 
polyclonal antibody raised against E. coli O157:H7, and since it is specific and sensitive 
for E. coli O157:H7, it was used as the capture antibody in all future assays.  
The species and concentration of the detector antibody was important to consider 
when PG was used in an immunoassay format. PG has previously shown a range of 
affinities for different species of antibody (1, 4, 14). However, PG has not shown a high 
affinity towards chicken (1, 14) or mouse (1, 4) antibodies, which suggested that they 
could be used as detector antibodies. HRP labeled chicken and mouse antibodies, raised 
against E. coli O157:H7, were tested for use as detector antibodies, but were found to be 
insensitive and non-specific for the target organism; when compared to goat antibodies 
raised against E. coli O157:H7 (data not shown). Goat polyclonal antibodies raised 
against E. coli O157:H7 were implemented as the capture and detector antibody for all 
future assays.  
Further investigation was required to avoid displacement of the goat species 
capture antibodies on PG by the goat species detector antibodies, which the Fc binding 
domain has similar affinity for. In Figure 11, 1.0 μg/ml of detector antibody produced the 
greatest signal to noise ratios at all concentrations of E. coli O157:H7. Due to elevated 
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background signals, the signal to noise ratios decreased as the concentration of detector 
antibody increased. These results suggested that the excess detector antibody may have 
displaced the same-species capture antibody. To test for displacement of the capture 
antibody by the detector antibody fluorescence values produced by wells that contained 
bacteria were compared to fluorescence values produced wells that lacked bacteria. 
Figure 12 shows that when E. coli O157:H7 was absent from the environment, minimal 
fluorescence (< 300 pA) was produced, which indicated that the detector antibody did 
bind due to a lack of target. These results also indicated that the detector antibody did not 
bind to the PG present in the capture matrix, and that the Fc binding domains were 
effectively saturated with the capture antibody. The lack of fluorescence further indicated 
that the capture antibodies at 1.0 μg/ml was not displaced by the same-species detector 
antibodies, at 0.1 μg/ml through to 1.0 μg/ml. Goat species detector antibody at 1.0 μg/ml 
was implemented for all future assays using ELISA analysis.    
 Sensitivity of the immunoassay was a major consideration during the 
development of the alternative capture matrix. The limit of detection was used as a 
measure of sensitivity, which was based on the concentration of bacteria captured and 
subsequently detected by the immunoassay. Figure 13 shows the limit of detection was 
9.7 x 104 CFU/ml for E. coli O157:H7 by the streptavidin-biotin and the HSA-PG capture 
matrices. The HSA-PG capture matrix produced signal to noise ratios significantly (P < 
0.05) greater than the streptavidin-biotin capture matrix for all bacterial concentrations 
tested greater than 9.7 x 103 CFU/ml. The most significant difference produced between 
the capture matrices was for the lowest sample concentration, 9.7 x 104 CFU/ml. As the 
concentration of bacteria increased, the difference in signal to noise ratios decreased 
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between the two capture matrices. These results suggested that the bacterial target began 
to saturate the antigen binding sites for both matrices at 9.7 x 105 CFU/ml.  
The sensitivity of the two capture matrices was compared using RAPTOR 
analysis. Figure 14 shows the same sensitivity, or limit of detection, for the two capture 
matrices (streptavidin-biotin and HSA-PG) at 1.9 x 103 CFU/ml of E. coli O157:H7. At 
sample concentrations below 1.0 x 105 CFU/ml, a significant (P < 0.05) difference was 
not produced between the two capture matrices. These results indicated that at lower 
concentrations of E. coli O157:H7 the sensitivity was not improved by the HSA-PG 
capture matrix. The HSA-PG capture matrix produced significantly (P < 0.05) greater 
SALOD values for 1.0 x 105 through 1.3 x 106 CFU/ml, when compared to the 
streptavidin-biotin capture matrix. The increased SALOD values suggested the enhanced 
capture of bacteria in samples with concentrations greater than 1.0 x 105 CFU/ml of E. 
coli O157:H7.  
The amount of bacteria captured on the waveguide surface was quantified to 
compare the capture efficiency of the two capture matrices. Figure 17 shows that the 
greatest amount of GFP-E. coli O157:H7 captured was by the HSA-PG matrix, when 
compared to the streptavidin-biotin matrix at all concentrations tested. The number of 
cells counted on the HSA-PG waveguides was significantly (P < 0.05) greater when 
compared to the streptavidin-biotin treated waveguides, exclusively at low bacterial 
concentrations (3.7 x 106 CFU/ml). At higher concentrations, the amount of cells 
captured by the two matrices was not significantly (P < 0.05) different. Figure 18 shows 
the measured capture efficiency was 0.37% for the streptavidin-biotin capture matrix, and 
0.72% for the HSA-PG capture matrix, when GFP-E. coli O157:H7 was assayed at 3.7 x 
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106 CFU/ml in a 500 μl sample volume. GFP-E. coli O157:H7 was used in a previous 
study to measure the capture efficiency of the streptavidin-biotin capture matrix, which 
was reported at 0.54% for 1.0 x 106 CFU/ml in an 800 μl sample volume (36). This 
difference in capture efficiency for the streptavidin-biotin capture matrix could have been 
due to the change in sample volume, which was unavoidable due to a limitation in the 
equipment used. Capture efficiency was an invaluable tool used to examine the 
limitations of the capture matrices. Multiple strategies have been employed to investigate 
the lack of efficient capture: including sample volume, sample introduction and sample 
speed (36). More efficient target capture by capture matrices could lead to enhanced 
sensitivity by the immunoassay. These results indicated that when HSA and PG were 
used to uniformly orient the capture antibody the capture efficiency was improved.  
Contaminated food samples were added to the study to test the capabilities of the 
alternative capture matrix. Ground beef and spinach leaves were tested to determine if 
these food samples contained components that would interfere with the capture matrix. 
The supernatant of homogenized ground beef was tested by RAPTOR analysis. Figures 
15 and 16 show the limit of detection of E. coli O157:H7 was 5.4 x 105 CFU/ml for the 
HSA-PG capture matrix, when homogenized beef and spinach supernatants were tested. 
The minimal baseline values produced by the biosensor (Appendix B) suggested that 
components in the beef supernatant did not interfere with the PG in the capture matrix. In 
contrast, baseline values produced by the biosensor for the spinach supernatant were 
extremely high (Appendix B). The inherent fluorescence from the chlorophyll (10), in 
spinach supernatants, could have enhanced the detection by the biosensor; which resulted 
in false SALOD values and high background noise. The presence of chlorophyll in a food 
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product is important to consider when fluorescence-based assays are used to detect 
contamination.  
Figure 15 shows the limit of detection for the streptavidin-biotin capture matrix 
was 5.4 x 106 CFU/ml of E. coli O157:H7 in ground beef supernatant. For both capture 
matrices the limit of detection in the ground beef supernatant was less sensitive when 
compared to limit of detection in PBS (Figure 14). This decrease in sensitivity may be 
caused by unknown components in the food sample. Large fat or protein particles in the 
beef supernatant may block antigen binding sites on the waveguide surface, which may 
have led to decreased sensitivity of the assay (6). Figure 15 shows greater sensitivity by 
the HSA-PG matrix when compared to streptavidin-biotin in ground beef supernatant. 
The difference in limits of detection between the capture matrices could be explained by 
the uniform orientation of the antibodies by HSA-PG, and the random orientation of 
antibodies by the streptavidin-biotin capture matrix. Uniform antibody orientation has 
previously shown greater antibody activity when compared to random orientation (24, 
40).   
An alternative fluorophore was tested for enhanced sensitivity in the biosensor 
assay when the HSA-PG capture matrix was used. According to the manufacturer, Pierce 
Biotechnology (Rockford, IL), the DyLight™649 fluorophore is more photo-stable, and 
produces more intense fluorescence when compared to the Cy5 fluorophore.  Figure 19 
shows the detection fluorophores did not produce significantly (P < 0.05) different 
SALOD values. These results suggested that the alternative fluorophore failed to enhance 
the sensitivity of the RAPTOR assay.   
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Precision was used to measure the reproducibility of the RAPTOR assay, which 
was a critical characteristic for the immunoassay. Many parameters could diminish 
precision, e.g., approaching the detection limit of the assay. According to the 
manufacturer, Research International (Monroe, WA), the detection limits of RAPTOR 
assays vary depending on the nature of the target. Detection limits are lower for bacterial 
toxins (0.1 ng/ml to 1,000 ng/ml), as compared to whole bacterial cells (30 CFU/ml to 1.0 
x 107 CFU/ml). In this study the detection limits of E. coli O157:H7 were compared to 
the precision of the assay. Table 13 shows a total of 136 samples that were assayed using 
the RAPTOR biosensor, to compare the capture of E. coli O157:H7 by streptavidin-biotin 
and HSA-PG. The precision of both capture matrices was nearly identical, with the 
exception of 1.0 x 102 CFU/ml. The precision of detection, at and below 1.0 x 103 
CFU/ml of the target bacteria, was below 100%. This decrease in precision indicated that 
the limit of detection was surpassed, and that the results of the assay were not reliable for 
sample concentrations below 1.0 x 103CFU/ml. Typically, 100% precision or 
reproducibility would be expected from an immunoassay when the health and safety of 
consumers is a priority.  
Table 13 shows the analysis of a total of 60 RAPTOR waveguides, which were 
performed to detect E. coli O157:H7 or GFP-E. coli O157:H7 in PBS. Nine waveguides 
treated with the streptavidin-biotin capture matrix produced highly variable (CoV > 10%) 
baseline values. HSA-PG treated waveguides were less variable, with only seven 
waveguides producing highly variable baseline values. As described in the Materials and 
Methods section, the data produced by a waveguide with a highly variable baseline was 
discarded and was not used for graph construction. Baseline variability could be caused 
 65 
 
by many factors, including a bowed waveguide (< 180º) or a waveguide that was longer 
or shorter than 38mm, which were perhaps limitations of the manufacturing process. 
Figures 14 through 19 did not include data produced by waveguides with a baseline CoV 
greater than ten percent. Table 13 shows all the waveguides despite the baseline 
variability.  
 
E. coli 
CFU/ml 
HSA-PG 
Positive/Negative 
Assay 
Precision 
Streptavidin-Biotin 
Positive/Negative 
Assay 
Precision 
101 0/2 0% 0/2 0% 
102 3/9 25% 1/11 8% 
103 8/6 57% 8/6 57% 
104 10/0 100% 10/0 100% 
105 6/0 100% 6/0 100% 
106 12/0 100% 12/0 100% 
107 6/0 100% 6/0 100% 
108 6/0 100% 6/0 100% 
TABLE 13. Precision of Capture Matrices  
 
In conclusion, the alternative capture matrix consisted of a 2 to 1 ratio of human 
serum albumin and streptococcal PG, which immobilized rabbit and goat antibody in a 
uniform orientation and captured targeted antigen. This uniform antibody orientation led 
to significantly improved capture efficiency of E. coli O157:H7. Further study is required 
to improve reliable detection below 1.0 x 104 CFU/ml for the RAPTOR biosensor. 
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APPENDICES 
 Appendix A: ELISA Analysis 
TABLE 14. Functional Albumin Binding Domain, HSA Role in Capture Matrix 
HSA in Columns (μg/ml)
0.0 0.0 0.5 0.5 1.0 1.0 0.0 0.0 0.5 0.5 1.0 1.0
0.0 μg/ml PG 121.5 125.7 120.1 130.7 138.3 131.5 151.8 129.5 140.3 140.7 134.4 130.4
0.25 μg/ml PG 121.2 134.2 967.9 1044.4 1545.5 1569.1 160.5 131.7 138.3 140.7 134.5 130.5
0.5 μg/ml PG 132.2 127.1 1172.5 1231.9 1848.1 1864.9 138.2 125.3 131.7 131.5 134.0 133.2
1.0 μg/ml PG 119.8 130.1 1216.3 1344.5 1943.5 1907.6 136.9 123.3 133.4 143.7 128.9 129.7
2.5 μg/ml PG 122.5 134.2 1380.9 1336.1 1991.1 1997.7 141.1 136.8 132.5 138.1 132.2 132.6
5.0 μg/ml PG 110.7 153.9 1555.3 1518.7 2147.5 2132.7 138.5 120.8 127.3 128.1 132.0 126.0
10.0 μg/ml PG 117.1 148.8 1605.5 1570.8 2212.6 2140.0 158.1 136.9 136.6 139.2 134.8 137.7
20.0 μg/ml PG 139.2 157.5 1583.2 1567.1 2180.5 2222.2 142.6 135.6 147.9 133.7 139.5 137.3
0.0 μg/ml PG 148.7 168.1 158.5 158.6 151.4 156.8 185.8 170.3 169.2 173.6 163.6 144.0
0.25 μg/ml PG 139.8 180.0 985.0 997.9 1488.4 1485.6 221.3 197.3 166.1 186.1 147.3 150.1
0.5 μg/ml PG 153.2 176.0 1565.4 1372.8 2207.2 2119.1 205.8 156.8 141.0 173.5 141.4 138.5
1.0 μg/ml PG 153.6 157.8 1362.4 1650.2 2038.4 2318.9 257.4 163.2 143.3 154.9 150.5 139.9
2.5 μg/ml PG 125.4 160.4 1343.0 1335.4 1666.3 1891.0 148.7 158.8 141.6 149.8 139.2 155.1
5.0 μg/ml PG 119.9 135.4 1270.4 1267.8 1750.9 1763.3 137.6 133.7 131.9 126.4 138.6 135.8
10.0 μg/ml PG 127.0 176.0 1284.0 1294.7 1741.9 1715.2 143.7 137.4 126.4 120.7 129.0 127.4
20.0 μg/ml PG 148.1 169.6 1264.1 1255.6 1609.3 1641.3 140.1 143.4 145.3 140.7 137.4 139.5
0.0 μg/ml PG 134.6 150.6 146.2 148.4 144.2 150.1 160.8 162.6 166.4 167.8 153.8 159.1
0.25 μg/ml PG 144.6 157.2 1054.0 1144.2 1751.6 1788.0 171.6 174.2 164.6 171.0 147.9 168.1
0.5 μg/ml PG 150.9 176.1 1698.5 1698.2 2433.0 2393.8 159.9 162.0 142.1 152.1 138.2 147.4
1.0 μg/ml PG 135.3 161.5 1257.5 1348.0 2045.4 2037.5 155.7 171.5 146.8 143.8 141.8 158.3
2.5 μg/ml PG 137.1 170.5 1599.6 1573.7 2423.7 2467.9 168.3 165.8 162.2 155.5 144.3 134.8
5.0 μg/ml PG 112.7 137.0 1125.0 1046.9 1910.6 2060.7 127.5 129.4 130.1 131.8 134.2 123.1
10.0 μg/ml PG 133.7 203.2 1107.9 1107.0 1542.3 1569.7 143.6 147.4 133.1 142.1 134.7 133.3
20.0 μg/ml PG 139.2 146.7 1024.8 1119.4 1533.8 1590.1 140.5 144.8 141.5 147.2 141.8 141.2
No Bold Indicates Native PG Bold Indicates Recombinant PG  
 
TABLE 15. Alternative Albumin Species 
Albumin in columns (µg/ml)
1 OVA 1 OVA 5 OVA 5 OVA 1 BSA 1 BSA 5 BSA 5 BSA 1 HSA 1 HSA 5 HSA 5 HSA
0 µg/ml PG 283.9 206.0 187.9 185.4 258.7 279.2 188.8 217.8 253.0 261.4 173.7 215.6
0.25 µg/ml PG 318.6 273.7 185.2 182.3 303.0 291.8 327.4 354.0 2615.2 2601.9 2781.5 2889.5
0.5 µg/ml PG 289.4 255.1 186.9 187.3 320.5 319.2 453.2 383.0 3056.6 3079.6 3245.5 3389.8
1 µg/ml PG 317.2 285.3 186.1 188.6 382.3 357.4 549.1 591.0 3269.9 3368.2 3524.3 3692.3
2.5 µg/ml PG 224.1 272.1 197.0 192.5 434.5 465.4 705.6 709.1 3353.6 3380.7 3959.2 3934.0
5 µg/ml PG 237.0 348.8 245.5 211.4 466.3 488.8 915.1 864.9 3381.7 3363.5 3903.6 3926.4
No PG 181.3 244.7 244.9 154.1 258.3 254.2 250.6 242.7 300.4 258.0 209.7 234.9
PG in columns (µg/ml)
0.0 0.0 0.25 0.25 0.5 0.5 1.0 1.0 2.5 2.5 5.0 5.0
No Albumin 341.4 432.3 552.3 639.8 754.2 804.2 838.9 1227.0 1375.8 1471.7 1786.3 1869.4
Albumin in columns (µg/ml)
 
1 OVA 1 OVA 5 OVA 5 OVA 1 BSA 1 BSA 5 BSA 5 BSA 1 HSA 1 HSA 5 HSA 5 HSA
0 µg/ml PG 256.7 287.9 221.5 272.7 278.7 266.1 182.9 258.9 269.6 288.0 236.2 240.5
0.25 µg/ml PG 264.6 322.7 279.8 261.3 353.2 327.8 343.6 312.2 2745.5 2732.9 3043.3 3024.1
0.5 µg/ml PG 287.2 282.1 304.9 293.8 348.7 344.1 543.2 383.0 3188.7 3121.8 3413.9 3413.0
1 µg/ml PG 318.5 360.6 304.3 290.1 391.4 382.9 594.5 531.2 3447.2 3552.8 3670.1 3761.8
2.5 µg/ml PG 292.8 342.3 333.6 262.4 447.7 469.9 763.7 748.4 3471.6 3482.8 3856.7 3975.0
5 µg/ml PG 292.4 367.4 338.5 327.7 503.3 564.2 870.9 892.0 3460.0 3442.9 3847.0 3935.9
No PG 261.3 221.0 277.4 210.3 278.3 269.9 206.2 216.6 305.6 242.2 228.9 255.8
PG in columns (µg/ml)
0.0 0.0 0.25 0.25 0.5 0.5 1.0 1.0 2.5 2.5 5.0 5.0
No Albumin 482.5 575.4 882.6 637.6 796.7 900.8 825.1 1086.6 1536.8 1445.1 1753.2 2252.4  
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TABLE 15. Alternative Albumin Species (Continued) 
Albumin in columns (µg/ml)
1 OVA 1 OVA 5 OVA 5 OVA 1 BSA 1 BSA 5 BSA 5 BSA 1 HSA 1 HSA 5 HSA 5 HSA
0 µg/ml PG 243.6 278.9 285.8 264.6 294.2 370.9 291.9 285.1 291.8 351.8 263.4 294.8
0.25 µg/ml PG 280.6 322.8 270.6 269.1 383.2 418.3 388.5 395.1 3122.7 3117.1 3304.2 3608.9
0.5 µg/ml PG 356.0 277.9 290.6 277.9 499.7 348.5 438.5 476.3 3569.9 3534.5 3695.1 3447.3
1 µg/ml PG 417.7 313.3 313.4 370.2 454.9 366.0 587.4 576.9 3669.6 3775.5 4012.5 4225.8
2.5 µg/ml PG 313.5 376.7 385.7 329.1 490.8 478.9 753.2 764.0 3733.5 3753.3 4010.9 4091.0
5 µg/ml PG 332.0 360.2 405.2 473.7 648.5 598.2 931.7 999.6 3681.5 3771.9 3870.9 3870.8
No PG 209.2 265.1 276.0 216.5 309.1 272.3 248.0 235.6 247.3 313.8 261.9 245.5
PG in columns (µg/ml)
0.0 0.0 0.25 0.25 0.5 0.5 1.0 1.0 2.5 2.5 5.0 5.0
No Albumin 490.6 717.7 739.0 1021.0 825.1 798.4 1214.2 929.5 1129.4 1123.8 909.7 1119.3  
 
TABLE 16. HSA Role in Capturing Bacteria 
PG in Columns (μg/ml)
0.0 0.0 0.25 0.25 0.5 0.5 1.0 1.0 2.5 2.5 5.0 5.0
No Bacteria 142.4 156.4 162.0 179.6 176.5 187.7 174.2 182.0 174.7 181.7 197.5 190.9
4.70E+07 1524.2 1239.7 2741.1 2778.8 2924.7 2810.5 2883.3 2866.0 2855.7 2792.6 2844.2 2856.5
4.70E+06 449.9 373.1 2431.2 2563.4 2551.7 2630.7 2814.7 2529.5 2835.8 2845.2 2797.3 2862.5
4.70E+05 165.0 155.6 1599.6 1755.5 1877.2 2027.4 2201.0 2081.7 2235.8 2217.2 2288.3 2310.1
4.70E+04 136.8 134.7 1287.0 1284.8 1476.1 1643.3 1888.5 1733.4 1817.3 1766.8 1961.6 1979.6
4.70E+03 119.9 116.0 1015.0 1156.6 1273.9 1393.9 1617.6 1503.8 1742.0 1628.1 1691.9 1842.3
4.70E+02 112.7 112.1 951.1 1023.7 1337.4 1292.5 1408.8 1419.4 1443.9 1481.4 1512.5 1540.9
4.70E+01 105.3 115.8 799.9 930.8 1279.1 1235.3 1349.6 1339.6 1434.8 1401.5 1473.9 1500.4
No Bacteria 145.5 146.4 175.5 184.3 178.6 185.7 169.1 175.4 179.3 180.7 197.5 193.0
4.70E+07 1344.2 1264.4 3102.7 3152.6 3280.2 3240.1 3270.6 3266.1 3218.9 3233.4 3192.5 3189.9
4.70E+06 392.8 303.0 3150.1 3066.3 3102.6 2839.1 2830.7 3002.7 2935.2 2937.8 3159.7 3173.7
4.70E+05 154.5 138.6 2039.2 2100.1 2151.4 2208.6 2240.3 2365.5 2350.2 2427.0 2479.2 2448.0
4.70E+04 141.2 125.4 1859.5 1859.3 2029.2 1980.4 2133.2 2192.6 2286.9 2182.5 2329.6 2367.2
4.70E+03 116.8 123.3 1730.8 1673.5 1863.0 1862.2 2145.3 1963.9 2233.5 2336.7 2165.5 2363.7
4.70E+02 123.0 108.7 1509.9 1524.9 1695.3 1636.0 1884.6 1764.5 1890.9 1928.5 1904.5 2009.8
4.70E+01 111.9 123.1 1475.3 1475.7 1706.6 1668.9 1772.1 1813.6 1815.0 1848.4 1916.0 1965.5
No Bacteria 133.6 156.3 146.7 158.6 152.2 160.2 162.1 169.6 190.7 201.8 189.5 194.7
4.70E+07 1343.1 1064.5 3012.3 3162.5 3290.1 3244.0 3267.6 3265.0 3154.1 3238.5 3162.3 3191.9
4.70E+06 370.5 279.4 2824.8 2843.5 2911.1 3040.8 3050.0 3155.0 3311.8 3112.6 3135.1 3105.0
4.70E+05 177.6 137.2 2188.7 2128.9 2267.7 2262.9 2380.5 2481.7 2613.2 2480.9 2444.5 2382.7
4.70E+04 124.1 126.4 1816.6 1825.3 2032.3 2010.3 1990.0 2026.3 2123.8 1911.4 1939.7 1772.2
4.70E+03 118.6 113.5 1699.6 1849.7 1917.4 1836.0 1792.6 1787.7 1884.6 1773.5 1830.1 1738.4
4.70E+02 119.1 119.7 1660.8 1658.0 1791.3 1603.7 1709.5 1702.6 1881.5 1768.6 1758.6 1726.1
4.70E+01 114.5 129.9 1610.2 1463.8 1642.9 1615.4 1757.3 1702.0 1779.4 1737.2 1678.0 1651.2
E. coli O157:H7 in Rows (CFU/ml)  
 
TABLE 17. Optimal Ratio of HSA to PG 
PG in columns (μg/ml)
0.0 0.5 1.0 2.5 5.0 10.0 0.0 0.5 1.0 2.5 5.0 10.0
0 μg/ml HSA 1746.1 3675.8 5101.3 5678.2 5961.1 6329.3 354.8 399.8 723.4 403.2 557.5 760.0
0 μg/ml HSA 2823.3 3974.7 5264.7 5754.9 5948.0 6246.4 326.2 433.7 456.9 430.9 550.5 622.3
HSA in columns (μg/ml)
1.0 1.0 5.0 5.0 10.0 10.0 1.0 1.0 5.0 5.0 10.0 10.0
0.0 μg/ml PG 1124.8 1026.1 968.0 1050.0 1070.1 1056.1 114.7 103.6 111.1 119.9 156.2 127.9
0.5 μg/ml  PG 6233.9 6542.3 6769.8 6716.6 6725.1 6490.1 402.6 401.8 585.5 625.8 634.9 656.0
1.0 μg/ml  PG 6309.1 6267.5 6723.4 6504.4 6702.4 6499.8 437.9 462.8 740.7 741.0 765.1 875.4
2.5 μg/ml  PG 6187.0 6294.2 6578.0 6400.9 6549.4 6304.0 641.8 654.6 849.3 863.3 967.5 1007.4
5.0 μg/ml  PG 6102.8 6207.8 6581.1 6433.4 6511.9 6461.5 607.5 625.1 857.6 882.3 962.2 1012.7
10.0 μg/ml PG 6123.5 6386.5 6562.1 6527.9 6574.4 6597.5 717.8 745.0 1035.6 994.8 1106.9 1147.5
No Bold Indicates 8.1x107 CFU/ml E. coli  O157:H7 Bold indicates no bacteria  
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TABLE 18. Species Specific Fc Binding Domain 
PG in Columns (μg/ml)
0.0 0.0 0.5 0.5 1.0 1.0
0 μg/ml IgG 90.1 95.2 93.5 92.6 94.5 97.3
0.25 μg/ml IgG 92.9 92.2 692.9 693.9 643.1 672.2
0.5 μg/ml IgG 97.4 94.6 994.8 993.2 1387.0 1402.0
1.0 μg/ml IgG 93.3 91.4 1391.8 1407.7 1499.2 1501.3
0 μg/ml IgG 92.0 88.3 90.6 92.7 89.2 91.1
0.25 μg/ml IgG 99.5 84.5 88.7 88.3 88.1 92.8
0.5 μg/ml IgG 90.3 85.7 88.2 88.7 88.9 89.9
1.0 μg/ml IgG 88.1 88.1 89.0 87.1 89.6 91.9
0 μg/ml IgG 88.4 90.2 89.4 89.0 91.1 95.6
0.25 μg/ml IgG 93.2 98.0 602.2 593.8 653.1 772.2
0.5 μg/ml IgG 94.7 90.5 1394.8 1393.1 1388.1 1472.0
1.0 μg/ml IgG 98.5 95.9 1491.8 1411.8 1497.5 1521.4
0 μg/ml IgG 88.1 85.9 88.8 89.6 87.4 88.6
0.25 μg/ml IgG 90.2 93.4 92.1 91.6 94.0 103.1
0.5 μg/ml IgG 96.5 91.7 88.8 88.1 81.6 85.2
1.0 μg/ml IgG 94.0 93.2 96.1 93.1 94.4 91.1
0 μg/ml IgG 94.3 95.3 93.4 93.8 94.4 100.5
0.25 μg/ml IgG 91.8 98.6 640.3 632.2 646.0 631.8
0.5 μg/ml IgG 100.5 109.8 1181.0 1192.3 1088.2 1085.0
1.0 μg/ml IgG 103.2 119.7 1372.3 1304.4 1367.0 1313.2
0 μg/ml IgG 97.6 91.5 92.7 89.4 90.6 93.9
0.25 μg/ml IgG 130.5 111.4 105.7 109.0 104.6 101.8
0.5 μg/ml IgG 108.0 112.4 100.7 112.4 102.4 119.3
1.0 μg/ml IgG 109.9 101.6 134.9 112.3 102.9 103.6
Bold Indicates HRP goat anti- rabbit and mouse anti- E. coli O157:H7
No Bold Indicates HRP mouse anti- rabbit and goat anti- E. coli  O157:H7  
 
TABLE 19. Optimal Capture Antibody Species 
HSA in Columns (μg/ml)
0.0 0.0 0.5 0.5 1.0 1.0 0.0 0.0 0.5 0.5 1.0 1.0
0.0 μg/ml PG 93.3 95.6 111.9 109.5 124.8 107.4 132.8 137.8 115.9 113.5 121.2 106.6
0.5 μg/ml PG 108.7 103.1 340.6 334.8 603.5 672.0 152.2 147.5 523.6 552.9 819.1 810.1
1.0 μg/ml PG 117.3 131.2 397.0 405.0 738.5 742.9 149.6 143.9 940.7 945.8 921.1 1011.2
2.5 μg/ml PG 107.7 107.2 446.4 489.4 849.5 904.5 193.1 212.0 1014.7 989.6 1156.7 1488.4
0.0 μg/ml PG 119.1 101.9 105.1 111.3 121.8 134.7 166.8 182.7 139.8 159.5 140.8 143.8
0.5 μg/ml PG 126.8 116.9 116.5 129.5 109.6 114.0 157.3 157.8 145.1 162.7 145.1 146.4
1.0 μg/ml PG 109.7 129.7 112.8 114.3 146.0 111.5 207.6 169.8 136.5 160.8 154.2 164.0
2.5 μg/ml PG 125.9 114.2 127.7 125.7 130.6 137.8 171.8 155.5 163.3 168.2 156.6 156.7
0.0 μg/ml PG 120.3 105.9 92.6 120.0 131.5 119.2 128.8 146.3 117.4 106.5 126.0 114.7
0.5 μg/ml PG 108.6 112.1 464.3 476.3 886.2 828.7 166.5 164.4 586.1 564.0 996.1 970.9
1.0 μg/ml PG 112.8 109.4 657.7 659.8 1030.4 910.4 142.4 145.9 671.1 674.9 1163.3 1439.9
2.5 μg/ml PG 124.3 136.7 644.6 712.9 1293.0 1117.3 183.0 134.8 712.3 848.9 1344.3 1502.8
0.0 μg/ml PG 105.8 134.3 93.4 102.0 135.9 118.2 210.4 128.2 115.3 126.6 139.3 129.9
0.5 μg/ml PG 93.0 105.8 109.0 119.7 113.1 131.9 185.3 143.4 125.6 131.5 128.4 134.1
1.0 μg/ml PG 91.6 101.0 115.8 132.4 93.2 104.9 247.1 193.9 124.6 143.7 130.2 152.2
2.5 μg/ml PG 113.0 106.1 118.0 130.7 140.5 152.4 192.9 207.9 172.5 167.6 152.2 170.4
0.0 μg/ml PG 104.1 118.4 99.4 365.8 93.2 110.5 137.2 163.3 121.7 119.2 111.5 117.9
0.5 μg/ml PG 106.3 115.8 395.9 410.1 785.3 812.8 171.1 172.2 527.4 528.2 1021.4 995.6
1.0 μg/ml PG 111.6 98.7 510.2 462.6 939.2 937.2 135.8 166.9 647.4 663.1 1136.6 1411.8
2.5 μg/ml PG 97.7 135.1 593.7 555.3 1019.4 1047.1 174.8 159.8 787.3 859.9 1342.5 1703.2
0.0 μg/ml PG 129.7 103.5 129.1 101.4 101.7 101.1 189.0 154.3 125.9 134.5 140.2 149.5
0.5 μg/ml PG 120.4 115.2 114.5 126.3 147.4 171.0 197.3 148.0 137.6 123.3 149.7 146.3
1.0 μg/ml PG 110.7 109.9 130.1 118.2 103.7 101.8 204.2 227.6 151.7 150.7 140.5 152.2
2.5 μg/ml PG 97.0 119.0 132.9 121.6 122.5 153.8 213.5 212.1 176.1 165.2 164.3 169.0
Bold indicates PG lacking ABD
No Bold Indicates Rabbit anti- Goat and Mouse anti- Rabbit
Italics indicate Goat anti- E. coli O157:H7 and Mouse anti- Goat  
74 
 
 Appendix A: (Continued) 
 
TABLE 20. Optimal Concentration of Detector Antibody 
HRP goat anti E. coli O157:H7 in Columns (μg/ml)
1.0 1.0 2.5 2.5 5.0 5.0
3.0E+08 7454.3 8396.7 8158.9 7386.7 7414.3 7830.8
3.0E+07 7246.4 7924.8 7819.1 7454.5 7467.1 7337.9
3.0E+06 5887.1 6487.0 7122.4 6892.7 7150.1 7117.9
3.0E+05 2113.9 2357.2 3008.6 2865.5 3557.0 3459.8
3.0E+04 1191.3 1318.7 1646.9 1604.3 2147.9 2218.6
3.0E+03 1041.3 1116.6 1526.6 1470.1 2161.9 1979.5
1.5E+07 1030.2 1118.8 1530.2 1376.5 1933.9 1862.0
No Bacteria 1257.1 1372.3 1784.7 1656.7 2229.4 2229.1
3.0E+08 8570.0 8511.2 8420.4 8491.2 8603.5 8335.1
3.0E+07 8326.0 8585.6 8786.3 8824.7 8528.1 8279.8
3.0E+06 7950.3 8187.4 8607.0 8670.4 8747.8 8623.5
3.0E+05 4006.4 4006.6 4842.5 4463.9 5277.0 5029.3
3.0E+04 1768.8 1908.4 2281.1 2288.1 2591.5 2547.3
3.0E+03 1466.3 1495.8 1925.2 1841.8 2446.4 2445.9
1.5E+07 1437.4 1325.7 1760.9 1727.6 2437.2 2070.2
No Bacteria 1478.7 1370.9 1981.0 2128.8 2886.9 2545.5
3.0E+08 6850.5 6956.6 7310.9 7229.6 7441.9 7269.4
3.0E+07 6941.1 7097.3 7393.7 7128.7 7474.1 7365.0
3.0E+06 6699.5 6677.4 7307.0 7054.4 7364.7 7335.9
3.0E+05 3323.8 3247.1 4093.6 4023.1 4741.9 4593.5
3.0E+04 1283.6 1355.0 1667.3 1661.7 2042.7 2041.9
3.0E+03 1092.3 1166.3 1609.7 1656.4 2070.9 2067.4
1.5E+07 1055.8 1103.2 1617.1 1630.4 2064.6 2035.6
No Bacteria 1149.7 1138.0 1828.6 1798.2 2625.5 2697.2
Bold Indicates E. coli K-12 (CFU/ml)
No Bold Indicates E. coli O157:H7 (CFU/ml)  
 
TABLE 21. The Limit of Detection Using ELISA, Capture Antibody Displacement  
Concentration of HRP goat anti E. coli O157:H7 (μg/ml)
0.1 0.1 0.5 0.5 1.0 1.0 0.1 0.1 0.5 0.5 1.0 1.0
No Bacteria 89.6 86.1 155.3 218.5 329.2 297.8 96.9 96.8 203.6 207.8 247.9 235.4
K-12 (6.0x10^6) 85.4 84.4 137.8 150.3 284.6 208.4 95.5 94.0 198.5 196.7 230.9 229.1
O157 (9.7x10^2 81.3 83.6 132.9 154.0 210.4 223.9 86.1 88.0 161.9 132.7 237.2 260.4
O157 (9.7x10^3 96.7 99.4 146.7 182.2 300.3 272.3 98.6 97.7 106.8 107.9 217.4 247.5
O157 (9.7x10^4 321.3 317.1 650.9 773.9 1027.0 1089.0 349.8 317.6 605.1 617.4 1070.9 1063.9
O157 (9.7x10^5 1591.9 1399.8 4494.9 3945.1 5143.7 5388.6 2534.4 2527.4 5969.6 5451.6 6958.3 6994.6
O157 (9.7x10^6 2461.7 2353.1 5819.7 5947.2 7047.7 6940.5 3737.0 3735.9 6250.2 6274.6 7906.0 7936.7
O157 (9.7x10^7 1697.2 1735.8 5084.4 4868.8 6241.9 6216.4 2396.0 2446.9 5913.9 5884.7 6862.2 6674.8
No Bacteria 95.1 96.3 168.1 227.9 356.8 376.5 81.4 80.4 166.9 212.5 264.7 326.7
K-12 (6.0x10^6) 99.1 95.7 142.3 161.5 297.3 261.3 79.1 81.1 138.0 124.8 240.2 177.7
O157 (9.7x10^2 89.0 86.2 141.9 190.0 201.4 354.2 84.2 93.1 156.2 139.1 254.8 285.2
O157 (9.7x10^3 93.7 96.1 131.4 203.1 233.3 334.6 102.2 97.5 166.9 184.8 278.0 301.8
O157 (9.7x10^4 375.1 338.1 620.2 641.4 646.7 688.8 381.8 349.7 880.0 878.2 1181.3 1203.4
O157 (9.7x10^5 1744.9 1706.7 4213.0 4107.0 5188.0 5232.0 1728.8 1625.2 4348.3 4386.8 5607.5 5492.9
O157 (9.7x10^6 2840.1 2781.4 6257.0 6202.9 6861.5 6915.5 2694.0 2536.5 6199.0 6282.9 7092.1 6921.8
O157 (9.7x10^7 2476.7 2472.3 6068.0 5893.2 6985.6 6734.7 1766.8 1792.1 5139.6 4703.5 6232.1 6136.6
No Bacteria 92.2 95.7 269.9 224.8 335.3 376.4 84.1 90.5 147.0 204.0 287.7 355.8
K-12 (6.0x10^6) 90.2 99.5 247.2 244.0 264.1 283.5 77.4 82.9 121.2 138.7 208.5 220.2
O157 (9.7x10^2 99.3 96.8 141.1 118.4 196.3 197.9 82.2 86.5 169.9 129.0 190.6 193.8
O157 (9.7x10^3 92.4 91.8 178.2 147.8 230.2 242.9 100.2 103.8 315.2 171.0 229.6 234.6
O157 (9.7x10^4 367.5 398.5 607.9 629.5 687.3 697.8 354.9 347.9 826.1 813.3 1100.3 1146.0
O157 (9.7x10^5 1827.0 1466.1 4290.3 4267.6 5570.8 5237.6 1631.9 1552.4 4268.2 4270.9 5454.7 5417.0
O157 (9.7x10^6 3017.5 2330.4 6816.9 6480.9 7163.7 7080.6 2487.6 2533.1 6255.4 6297.5 7230.0 7237.2
O157 (9.7x10^7 2706.4 2121.4 6476.5 6352.5 7078.5 6895.3 1827.7 1759.6 5241.3 5260.0 6831.9 6892.4
No Bold Indicates Streptavidin-Biotin-IgG Bold Indicates HSA-PG-IgG  
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 Appendix B: RAPTOR Analysis 
 
TABLE 22. The Limit of Detection of Two Capture Matrices Using RAPTOR Analysis 
Strept-Biotin HSA-PG HSA-PG Strept-Biotin
Baseline Signals Baseline 1 691.9 520.5 535.3 822.1
Baseline 2 799.2 558.5 645.3 864.2
Baseline 3 913.2 590.3 747.5 949.9
Baseline 4 1013.1 622.6 820.8 1115.6
Normalization 
Coefficients B1/LC = B1N 1.3 1.0 1.0 1.6
B2/LC = B2N 1.4 1.0 1.2 1.5
B3/LC = B3N 1.5 1.0 1.3 1.6
B4/LC = B4N 1.6 1.0 1.3 1.8
Normalized 
Baselines B1/ B4N 425.2 520.5 406.0 458.8
B2/B4N 491.1 558.5 489.5 482.3
B3/B4N 561.2 590.3 567.0 530.1
B4/B4N 622.6 622.6 622.6 622.6
Average 525.0 573.0 521.3 523.5
STDEV 85.5 43.7 94.2 72.5
%CoV 16.3 7.6 18.1 13.8
E. coli O157:H7 
Signals 10^-6 1139.7 651.9 917.3 1169.5
10^-5 1228.2 685.2 965.9 1303.5
10^-4 1357.3 728.3 1099.6 1333.7
Normalized Ec 
Signals 10^-6/B4N 700.4 651.9 695.8 652.7
10^-5/B4N 754.8 685.2 732.7 727.5
10^-4/B4N 834.1 728.3 834.1 744.3
Limit of Detection LOD 781.6 704.0 804.0 740.8
E. coli O157:H7 
SALOD 4.0E+01 -81.2 -52.1 -108.2 -88.1
4.0E+02 -26.8 -18.8 -71.4 -13.4
4.0E+03 52.5 24.3 30.1 3.5  
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TABLE 22. The Limit of Detection of Two Capture Matrices Using RAPTOR Analysis 
(Continued) 
Strept-Biotin Strept-Biotin HSA-PG HSA-PG
Baseline Signals Baseline 1 479.5 454.9 501.8 579.9
Baseline 2 504.5 478.0 562.7 607.6
Baseline 3 534.7 503.6 617.4 630.7
Baseline 4 570.1 521.6 665.4 649.7
Normalization 
Coefficients B1/LC = B1N 1.1 1.0 1.1 1.3
B2/LC = B2N 1.1 1.0 1.2 1.3
B3/LC = B3N 1.1 1.0 1.2 1.3
B4/LC = B4N 1.1 1.0 1.3 1.2
Normalized 
Baselines B1/ B4N 438.7 454.9 393.4 465.6
B2/B4N 461.6 478.0 441.1 487.8
B3/B4N 489.2 503.6 484.0 506.3
B4/B4N 521.6 521.6 521.6 521.6
Average 477.8 489.5 460.0 495.3
STDEV 35.8 29.2 55.3 24.2
%CoV 7.5 6.0 12.0 4.9
E. coli O157:H7 
Signals 10^-6 600.8 543.6 664.4 668.7
10^-5 653.4 568.3 735.1 693.8
10^-4 2008.6 1467.8 2447.5 1803.3
Normalized Ec 
Signals 10^-6/B4N 549.7 543.6 520.8 536.9
10^-5/B4N 597.8 568.3 576.2 557.0
10^-4/B4N 1837.7 1467.8 1918.6 1447.7
Limit of Detection LOD 585.1 577.1 625.9 567.9
E. coli O157:H7 
SALOD 1.3E+02 -35.4 -33.5 -105.0 -31.0
1.3E+03 12.7 -8.8 -49.6 -10.9
1.3E+06 1252.6 890.7 1292.7 879.9
HSA-PG HSA-PG Strept-Biotin Strept-Biotin
Baseline Signals Baseline 1 645.8 613.9 558 434.6
Baseline 2 660.5 627.2 567 450.8
Baseline 3 661 636.1 569.5 456
Baseline 4 672.5 652 577 466
Normalization 
Coefficients B1/LC = B1N 1.5 1.4 1.3 1.0
B2/LC = B2N 1.5 1.4 1.3 1.0
B3/LC = B3N 1.4 1.4 1.2 1.0
B4/LC = B4N 1.4 1.4 1.2 1.0
Normalized 
Baselines B1/ B4N 447.5 438.8 450.7 434.6
B2/B4N 457.7 448.3 457.9 450.8
B3/B4N 458.0 454.6 459.9 456.0
B4/B4N 466.0 466.0 466.0 466.0
Average 457.3 451.9 458.6 451.9
STDEV 7.6 11.4 6.3 13.1
%CoV 1.7 2.5 1.4 2.9
E. coli O157:H7 
Signals 10^-6 761.7 685.2 581.8 478.8
10^-5 802.7 702.3 621 492.9
10^-4 862.7 721.1 641.2 521.9
Normalized Ec 
Signals 10^-6/B4N 527.8 489.7 469.9 478.8
10^-5/B4N 556.2 502.0 501.5 492.9
10^-4/B4N 597.8 515.4 517.8 521.9
Limit of 
Detection LOD 480.0 486.2 477.6 491.2
E. coli O157:H7 
SALOD 2.1E+02 47.8 3.5 -7.7 -12.4
2.1E+03 76.2 15.7 23.9 1.7
2.1E+04 117.7 29.2 40.2 30.7  
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 Appendix B: (Continued) 
 
TABLE 22. The Limit of Detection of Two Capture Matrices Using RAPTOR Analysis 
(Continued) 
Strept-Biotin Strept-Biotin HSA-PG HSA-PG
Baseline Signals Baseline 1 672.7 584.7 576.1 402.8
Baseline 2 703.4 594.4 617.9 433.6
Baseline 3 731.0 612.9 641.7 465.5
Baseline 4 763.8 623.1 675.8 489.6
Normalization 
Coefficients B1/LC = B1N 1.7 1.5 1.4 1.0
B2/LC = B2N 1.6 1.4 1.4 1.0
B3/LC = B3N 1.6 1.3 1.4 1.0
B4/LC = B4N 1.6 1.3 1.4 1.0
Normalized 
Baselines B1/ B4N 431.2 459.4 417.4 402.8
B2/B4N 450.9 467.0 447.7 433.6
B3/B4N 468.6 481.6 464.9 465.5
B4/B4N 489.6 489.6 489.6 489.6
Average 460.1 474.4 454.9 447.9
STDEV 24.9 13.7 30.4 37.8
%CoV 5.4 2.9 6.7 8.4
E. coli O157:H7 
Signals 10^-5 796.0 637.5 721.2 519.8
10^-4 860.1 671.9 765.6 546.0
10^-3 1286.5 956.0 1050.0 782.6
Normalized Ec 
Signals 10^-5/B4N 510.2 500.9 522.5 519.8
10^-4/B4N 551.3 527.9 554.7 546.0
10^-3/B4N 824.7 751.2 760.7 782.6
Limit of Detection LOD 534.8 515.4 546.0 561.3
E. coli O157:H7 
SALOD 1.0E+02 -24.6 -14.5 -23.5 -41.5
1.0E+03 16.5 12.5 8.7 -15.3
1.0E+04 289.8 235.7 214.7 221.3
HSA-PG HSA-PG Strept-Biotin Strept-Biotin
Baseline Signals Baseline 1 618.0 519.0 615.4 476.2
Baseline 2 636.7 502.6 657.2 463.4
Baseline 3 668.0 506.7 694.9 479.8
Baseline 4 695.5 525.7 739.8 491.1
Normalization 
Coefficients B1/LC = B1N 1.3 1.1 1.3 1.0
B2/LC = B2N 1.4 1.1 1.4 1.0
B3/LC = B3N 1.4 1.1 1.4 1.0
B4/LC = B4N 1.4 1.1 1.5 1.0
Normalized 
Baselines B1/ B4N 436.4 484.8 408.5 476.2
B2/B4N 449.6 469.5 436.3 463.4
B3/B4N 471.7 473.4 461.3 479.8
B4/B4N 491.1 491.1 491.1 491.1
Average 462.2 479.7 449.3 477.6
STDEV 24.2 10.0 35.2 11.4
%CoV 5.2 2.1 7.8 2.4
E. coli O157:H7 
Signals 10^-5 722.6 546.7 759.9 522.9
10^-4 742.4 554.9 813.6 559.4
10^-3 1069.4 755.5 1163.6 804.1
10^-2 3811.5 2678.5 4411.0 3091.0
10^-1 6385.5 4378.0 7381.0 5340.5
Normalized Ec 
Signals 10^-5/B4N 510.2 510.7 504.4 522.9
10^-4/B4N 524.2 518.4 540.1 559.4
10^-3/B4N 755.1 705.8 772.4 804.1
10^-2/B4N 2691.3 2502.2 2928.1 3091.0
10^1/B4N 4508.9 4089.9 4899.7 5340.5
Limit of Detection LOD 534.7 509.7 555.0 511.9
E. coli O157:H7 
SALOD 1.0E+02 -24.4 1.0 -50.5 11.0
1.0E+03 -10.5 8.7 -14.9 47.5
1.0E+04 220.4 196.1 217.4 292.2
1.0E+05 2156.7 1992.5 2373.2 2579.1
1.0E+06 3974.2 3580.1 4344.7 4828.6  
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TABLE 23.The Limit of Detection in Ground Beef Homogenate Supernatant Fluid 
HSA-PG HSA-PG HSA-PG HSA-PG
Baseline Signals Baseline 1 474.7 397.5 322.6 301.4
Baseline 2 498.2 321.5 367.0 363.8
Baseline 3 456.1 394.0 325.2 345.4
Baseline 4 465.4 372.0 301.5 315.6
Normalization 
Coefficients B1/LC = B1N 1.6 1.3 1.1 1.0
B2/LC = B2N 1.5 1.0 1.1 1.1
B3/LC = B3N 1.4 1.2 1.0 1.1
B4/LC = B4N 1.5 1.2 1.0 1.0
Normalized 
Baselines B1/ B4N 307.5 322.2 322.6 287.9
B2/B4N 322.7 260.6 367.0 347.5
B3/B4N 295.5 319.3 325.2 330.0
B4/B4N 301.5 301.5 301.5 301.5
Average 306.8 300.9 329.1 316.7
STDEV 11.7 28.4 27.4 27.0
%CoV 3.8 9.4 8.3 8.5
E. coli O157:H7 
Signals 10^-2 559.7 488.5 351.6 350.5
10^-1 913.7 598.5 456.4 474.1
10^0 1313.6 864.5 551.9 508.0
Normalized Ec 
Signals 10^-2/B4N 362.6 395.9 351.6 334.8
10^-1/B4N 591.9 485.1 456.4 452.9
10^0/B4N 851.0 700.7 551.9 485.3
Limit of Detection LOD 341.9 386.1 411.3 397.7
E. coli O157:H7 
SALOD 5.7E+04 20.7 9.8 -59.7 -62.9
5.7E+05 250.0 99.0 45.1 55.2
5.7E+06 509.1 314.6 140.6 87.6  
Strept-Biotin Strept-Biotin HSA-PG HSA-PG
Baseline Signals Baseline 1 380.6 337.0 339.1 351.0
Baseline 2 335.3 280.5 336.1 321.2
Baseline 3 319.1 257.0 295.8 300.2
Baseline 4 306.6 270.3 292.2 299.2
Normalization 
Coefficients B1/LC = B1N 1.1 1.0 1.0 1.0
B2/LC = B2N 1.2 1.0 1.2 1.1
B3/LC = B3N 1.2 1.0 1.2 1.2
B4/LC = B4N 1.1 1.0 1.1 1.1
Normalized 
Baselines B1/ B4N 335.5 337.0 313.7 317.1
B2/B4N 295.6 280.5 310.9 290.2
B3/B4N 281.3 257.0 273.6 271.2
B4/B4N 270.3 270.3 270.3 270.3
Average 295.7 286.2 292.1 287.2
STDEV 28.5 35.2 23.4 21.9
%CoV 9.6 12.3 8.0 7.6
E. coli O157:H7 
Signals 10^-2 366.5 396.5 352.1 346.9
10^-1 646.6 815.5 646.3 664.0
10^0 835.1 850.9 726.3 855.0
Normalized Ec 
Signals 10^-2/B4N 323.1 396.5 325.7 313.4
10^-1/B4N 570.0 815.5 597.9 599.9
10^0/B4N 736.2 850.9 671.9 772.4
Limit of Detection LOD 381.2 391.8 362.2 353.0
E. coli O157:H7 
SALOD 5.4E+05 -58.1 4.7 -36.5 -39.6
5.4E+06 188.8 423.7 235.7 246.8
5.4E+07 355.0 459.1 309.7 419.4   
 Appendix B: (Continued) 
 
TABLE 23.The Limit of Detection in Ground Beef Homogenate Supernatant Fluid 
Strept-Biotin Strept-Biotin HSA-PG HSA-PG
Baseline Signals Baseline 1 323.8 453.9 331.9 330.5
Baseline 2 305.1 553.0 296.3 315.1
Baseline 3 307.7 605.0 288.6 316.1
Baseline 4 316.0 662.5 298.9 314.1
Normalization 
Coefficients B1/LC = B1N 1.0 1.4 1.0 1.0
B2/LC = B2N 1.0 1.9 1.0 1.1
B3/LC = B3N 1.1 2.1 1.0 1.1
B4/LC = B4N 1.1 2.2 1.0 1.1
Normalized 
Baselines B1/ B4N 306.3 204.8 331.9 314.5
B2/B4N 288.6 249.5 296.3 299.9
B3/B4N 291.0 273.0 288.6 300.8
B4/B4N 298.9 298.9 298.9 298.9
Average 296.2 256.5 303.9 303.5
STDEV 8.0 40.0 19.2 7.4
%CoV 2.7 15.6 6.3 2.4
E. coli O157:H7 
Signals 10^-2 390.5 693.0 323.7 357.1
10^-1 853.8 1086.5 446.5 682.0
10^0 1621.2 2254.5 617.9 873.9
Normalized Ec 
Signals 10^-2/B4N 369.4 312.7 323.7 339.8
10^-1/B4N 807.6 490.2 446.5 649.0
10^0/B4N 1533.5 1017.2 617.9 831.6
Limit of Detection LOD 320.3 376.4 361.4 325.6
E. coli O157:H7 
SALOD 1.5E+05 49.1 -63.8 -37.7 14.2
1.5E+06 487.3 113.8 85.1 323.4
1.5E+07 1213.2 640.7 256.5 506.0  
 
TABLE 24. The Limit of Detection in Spinach Homogenate Supernatant Fluid 
HSA-PG HSA-PG HSA-PG HSA-PG
Baseline Signals Baseline 1 891.3 929.8 844.0 805.2
Baseline 2 1163.1 1028.3 1036.1 1142.3
Baseline 3 1349.5 1056.5 1149.1 1242.9
Baseline 4 1518.2 989.9 1195.1 1308.1
Normalization 
Coefficients B1/LC = B1N 1.1 1.2 1.0 1.0
B2/LC = B2N 1.1 1.0 1.0 1.1
B3/LC = B3N 1.3 1.0 1.1 1.2
B4/LC = B4N 1.5 1.0 1.2 1.3
Normalized 
Baselines B1/ B4N 581.1 929.8 699.1 609.3
B2/B4N 758.4 1028.3 858.2 864.4
B3/B4N 879.9 1056.5 951.8 940.6
B4/B4N 989.9 989.9 989.9 989.9
Average 802.3 1001.1 874.7 851.1
STDEV 175.2 54.8 129.5 169.2
%CoV 21.8 5.5 14.8 19.9
E. coli O157:H7 
Signals 10^-2 2077.3 1313.5 1647.3 1657.0
10^-1 4603.5 2123.0 4312.0 3415.5
10^0 4785.0 3096.5 4862.0 3525.5
Normalized Ec 
Signals 10^-2/B4N 1354.4 1313.5 1364.5 1253.9
10^-1/B4N 3001.6 2123.0 3571.6 2584.7
10^0/B4N 3119.9 3096.5 4027.2 2667.9
Limit of Detection LOD 1327.8 1165.6 1263.3 1358.7
E. coli O157:H7 
SALOD 2.9E+05 26.6 147.9 101.1 -104.8
2.9E+06 1673.7 957.4 2308.3 1226.0
2.9E+07 1792.1 1930.9 2763.9 1309.2  
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TABLE 25. Cells Capture on Waveguide Surface, Capture Efficiency  
HSA-PG Strept-Biotin Strept-Biotin HSA-PG
Baseline Signals Baseline 1 502.9 346.2 375.8 429.5
Baseline 2 533.1 378 458.9 449.5
Baseline 3 602.9 387.7 516.8 462.4
Baseline 4 633.6 407.7 552.4 478.8
Normalization 
Coefficients B1/LC = B1N 1.5 1.0 1.1 1.2
B2/LC = B2N 1.4 1.0 1.2 1.2
B3/LC = B3N 1.6 1.0 1.3 1.2
B4/LC = B4N 1.6 1.0 1.4 1.2
Normalized 
Baselines B1/ B4N 323.6 346.2 277.4 365.7
B2/B4N 343.0 378.0 338.7 382.8
B3/B4N 387.9 387.7 381.4 393.7
B4/B4N 407.7 407.7 407.7 407.7
Average 365.6 379.9 351.3 387.5
STDEV 38.9 25.6 56.9 17.7
%CoV 10.6 6.8 16.2 4.6
E. coli O157:H7 
Signals 10^0 2288 1323.7 1837.3 1513.8
Normalized Ec 
Signals 10^0 1472.3 1323.7 1356.0 1289.0
Limit of Detection LOD 482.3 456.8 522.0 440.7
E. coli O157:H7 
SALOD 1.7E+08 989.9 866.9 834.0 848.3  
HSA-PG HSA-PG Strept-Biotin Strept-Biotin
Baseline Signals Baseline 1 657.5 547.2 690.2 673.8
Baseline 2 783 626.2 995.3 824.7
Baseline 3 887.6 705.7 1205.4 1002.7
Baseline 4 885.5 760.1 1358.7 1038.7
Normalization 
Coefficients B1/LC = B1N 1.2 1.0 1.3 1.2
B2/LC = B2N 1.3 1.0 1.6 1.3
B3/LC = B3N 1.3 1.0 1.7 1.4
B4/LC = B4N 1.2 1.0 1.8 1.4
Normalized 
Baselines B1/ B4N 564.4 547.2 386.1 493.1
B2/B4N 672.1 626.2 556.8 603.5
B3/B4N 761.9 705.7 674.3 733.8
B4/B4N 760.1 760.1 760.1 760.1
Average 689.6 659.8 594.3 647.6
STDEV 93.4 93.0 161.9 123.7
%CoV 13.5 14.1 27.2 19.1
E. coli O157:H7 
Signals 10^-1 3246 2315.5 4559.5 2904
Normalized Ec 
Signals 10^-1 2786.3 2315.5 2550.7 2125.1
Limit of Detection LOD 969.9 938.9 1080.1 1018.7
E. coli O157:H7 
SALOD 1.7E+07 1816.4 1376.6 1470.7 1106.4  
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TABLE 25. Cells Capture on Waveguide Surface, Capture Efficiency (Continued)  
 
HSA-PG Strept-Biotin Strept-Biotin HSA-PG
Baseline Signals Baseline 1 345.2 344.1 343.8 389.0
Baseline 2 580.5 388.2 421.8 536.3
Baseline 3 652.9 419.0 470.8 603.0
Baseline 4 737.2 443.6 511.6 648.7
Normalization 
Coefficients B1/LC = B1N 1.0 1.0 1.0 1.1
B2/LC = B2N 1.5 1.0 1.1 1.4
B3/LC = B3N 1.6 1.0 1.1 1.4
B4/LC = B4N 1.7 1.0 1.2 1.5
Normalized 
Baselines B1/ B4N 207.7 344.1 298.1 266.0
B2/B4N 349.3 388.2 365.7 366.7
B3/B4N 392.9 419.0 408.2 412.3
B4/B4N 443.6 443.6 443.6 443.6
Average 348.4 398.7 378.9 372.2
STDEV 101.4 42.9 62.6 77.5
%CoV 29.1 10.8 16.5 20.8
E. coli O157:H7 
Signals 10^0 2000.8 1549.4 2073.7 1037.1
Normalized Ec 
Signals 10^0 1204.0 1549.4 1798.1 709.2
Limit of Detection LOD 652.5 527.4 566.6 604.7
E. coli O157:H7 
SALOD 4.3E+08 551.4 1022.0 1231.4 104.5  
Strept-Biotin Strept-Biotin HSA-PG HSA-PG
Baseline Signals Baseline 1 441 362.1 373.2 498.3
Baseline 2 475.9 389.8 404.7 644.4
Baseline 3 517 412.9 420.2 663.7
Baseline 4 529.5 431.3 444.5 693.3
Normalization 
Coefficients B1/LC = B1N 1.2 1.0 1.0 1.4
B2/LC = B2N 1.2 1.0 1.0 1.7
B3/LC = B3N 1.3 1.0 1.0 1.6
B4/LC = B4N 1.2 1.0 1.0 1.6
Normalized 
Baselines B1/ B4N 359.2 362.1 362.1 310.0
B2/B4N 387.6 389.8 392.7 400.9
B3/B4N 421.1 412.9 407.7 412.9
B4/B4N 431.3 431.3 431.3 431.3
Average 399.8 399.0 398.5 388.8
STDEV 32.9 29.9 29.0 54.0
%CoV 8.2 7.5 7.3 13.9
E. coli O157:H7 
Signals 10^-1 2172.5 1622.7 2568.5 3575.7
Normalized Ec 
Signals 10^-1 1769.6 1622.7 2492.2 2224.4
Limit of Detection LOD 498.4 488.7 485.4 550.7
E. coli O157:H7 
SALOD 2.8E+07 1271.2 1134.0 2006.8 1673.7  
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TABLE 25. Cells Capture on Waveguide Surface, Capture Efficiency (Continued)  
Strept-Biotin HSA-PG HSA-PG Strept-Biotin
Baseline Signals Baseline 1 470.6 422.1 464.1 459.3
Baseline 2 492.5 432.4 497.6 481.9
Baseline 3 510.2 442.6 535.3 516.8
Baseline 4 530 456.5 568.4 540.9
Normalization 
Coefficients B1/LC = B1N 1.1 1.0 1.1 1.1
B2/LC = B2N 1.1 1.0 1.2 1.1
B3/LC = B3N 1.2 1.0 1.2 1.2
B4/LC = B4N 1.2 1.0 1.2 1.2
Normalized 
Baselines B1/ B4N 405.3 422.1 372.7 387.6
B2/B4N 424.2 432.4 399.6 406.7
B3/B4N 439.4 442.6 429.9 436.2
B4/B4N 456.5 456.5 456.5 456.5
Average 431.4 438.4 414.7 421.7
STDEV 21.8 14.7 36.4 30.6
%CoV 5.1 3.3 8.8 7.3
E. coli O157:H7 
Signals 10^-2 2114.8 2234.1 2867.5 2222
Normalized Ec 
Signals 10^-2 1821.5 2234.1 2303.0 1875.3
Limit of Detection LOD 496.8 482.5 523.8 513.5
E. coli O157:H7 
SALOD 1.1E+06 1324.7 1751.6 1779.2 1361.8  
Strept-Biotin HSA-PG HSA-PG Strept-Biotin
Baseline Signals Baseline 1 467 371.8 356.7 394.1
Baseline 2 518 422.6 409.9 490.6
Baseline 3 550.8 447.7 457.9 502.9
Baseline 4 565.4 446.7 485.8 544.5
Normalization 
Coefficients B1/LC = B1N 1.3 1.0 1.0 1.1
B2/LC = B2N 1.3 1.0 1.0 1.2
B3/LC = B3N 1.2 1.0 1.0 1.1
B4/LC = B4N 1.3 1.0 1.1 1.2
Normalized 
Baselines B1/ B4N 369.0 371.8 328.0 323.3
B2/B4N 409.3 422.6 376.9 402.5
B3/B4N 435.2 447.7 421.0 412.6
B4/B4N 446.7 446.7 446.7 446.7
Average 415.0 422.2 393.2 396.3
STDEV 34.5 35.5 52.1 52.2
%CoV 8.3 8.4 13.3 13.2
E. coli O157:H7 
Signals 10^0 2821.5 1475 1537.8 1538
Normalized Ec 
Signals 10^0 2229.2 1475.0 1414.0 1261.8
Limit of Detection LOD 518.4 528.8 549.6 552.8
E. coli O157:H7 
SALOD 1.8E+08 1710.7 946.2 864.5 708.9  
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TABLE 25. Cells Capture on Waveguide Surface, Capture Efficiency (Continued)  
HSA-PG Strept-Biotin Strept-Biotin HSA-PG
Baseline Signals Baseline 1 647.1 404.6 538.4 530.1
Baseline 2 693.5 422.6 593.2 549.6
Baseline 3 741.4 453.9 624.1 584
Baseline 4 762.7 463.1 639.1 607.1
Normalization 
Coefficients B1/LC = B1N 1.6 1.0 1.3 1.3
B2/LC = B2N 1.6 1.0 1.4 1.3
B3/LC = B3N 1.6 1.0 1.4 1.3
B4/LC = B4N 1.6 1.0 1.4 1.3
Normalized 
Baselines B1/ B4N 392.9 404.6 390.1 404.4
B2/B4N 421.1 422.6 429.8 419.2
B3/B4N 450.2 453.9 452.2 445.5
B4/B4N 463.1 463.1 463.1 463.1
Average 431.8 436.1 433.8 433.0
STDEV 31.3 27.2 32.3 26.3
%CoV 7.3 6.2 7.4 6.1
E. coli O157:H7 
Signals 10^-1 6583.5 3657.5 5626.5 4653
Normalized Ec 
Signals 10^-1 3997.4 3657.5 4077.0 3549.3
Limit of Detection LOD 525.8 517.7 530.6 511.9
E. coli O157:H7 
SALOD 7.8E+07 3471.6 3139.8 3546.4 3037.5  
HSA-PG HSA-PG Strept-Biotin Strept-Biotin
Baseline Signals Baseline 1 594 503.6 478.5 449
Baseline 2 613.8 533.9 503.3 474.1
Baseline 3 653.4 562.6 519.3 490.6
Baseline 4 679.4 587.2 526 503.9
Normalization 
Coefficients B1/LC = B1N 1.3 1.1 1.1 1.0
B2/LC = B2N 1.3 1.1 1.1 1.0
B3/LC = B3N 1.3 1.1 1.1 1.0
B4/LC = B4N 1.3 1.2 1.0 1.0
Normalized 
Baselines B1/ B4N 440.6 432.2 458.4 449.0
B2/B4N 455.2 458.2 482.2 474.1
B3/B4N 484.6 482.8 497.5 490.6
B4/B4N 503.9 503.9 503.9 503.9
Average 471.1 469.3 485.5 479.4
STDEV 28.5 31.0 20.2 23.6
%CoV 6.1 6.6 4.2 4.9
E. coli O157:H7 
Signals 10^-2 4240.5 2832.5 3388 3080
Normalized Ec 
Signals 10^-2 3145.1 2430.7 3245.7 3080.0
Limit of Detection LOD 556.7 562.2 546.2 550.3
E. coli O157:H7 
SALOD 1.1E+06 2588.4 1868.4 2699.5 2529.7  
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TABLE 26. A Comparison of DyLight™649 and Cy5 
DyLight Cy5 Cy5 DyLight Cy5 DyLight DyLight Cy5
Baseline Signals Baseline 1 916.3 541.6 465.1 587 3230.5 542.1 750.6 1742.7
Baseline 2 1029.8 575.4 488.4 634.8 3377.0 585.7 764.0 1742.2
Baseline 3 1127.2 600.6 519.3 689.2 3899.5 592.4 798.6 1764.3
Baseline 4 1202.7 632.4 549.8 724.6 3993.0 611.9 819.3 1776.6
Normalization 
Coefficients B1/LC = B1N 1.7 1.0 0.9 1.1 6.0 1.0 1.4 3.2
B2/LC = B2N 1.8 1.0 0.8 1.1 5.8 1.0 1.3 3.0
B3/LC = B3N 1.9 1.0 0.9 1.1 6.6 1.0 1.3 3.0
B4/LC = B4N 1.9 1.0 0.9 1.1 6.5 1.0 1.3 2.9
Normalized 
Baselines B1/ B4N 481.8 541.6 535.0 512.3 495.1 542.1 560.6 600.2
B2/B4N 541.5 575.4 561.8 554.0 517.5 585.7 570.6 600.1
B3/B4N 592.7 600.6 597.3 601.5 597.6 592.4 596.4 607.7
B4/B4N 632.4 632.4 632.4 632.4 611.9 611.9 611.9 611.9
Average 562.1 587.5 581.6 575.1 555.5 583.0 584.9 605.0
STDEV 65.2 38.5 42.4 52.8 57.9 29.5 23.5 5.8
%CoV 11.6 6.5 7.3 9.2 10.4 5.1 4.0 1.0
E. coli O157:H7 
Signals 10^-6 1287 659 583.3 768.7 3212.0 620.6 852.8 1817.7
10^-5 1357.3 703.2 615.9 805.2 3932.5 643.7 906.0 1804.8
10^-4 1477.6 761.6 691.2 887.3 4020.5 716.0 975.7 1849.0
Normalized Ec 
Signals 10^-6/B4N 676.7 659.0 670.9 670.9 492.2 620.6 636.9 626.1
10^-5/B4N 713.7 703.2 708.4 702.7 602.6 643.7 676.7 621.6
10^-4/B4N 776.9 761.6 795.0 774.4 616.1 716.0 728.7 636.8
Limit of Detection LOD 757.7 702.9 708.8 733.5 729.1 671.4 655.4 622.5
E. coli O157:H7 
SALOD 6.0E+01 -81.0 -43.9 -37.9 -62.6 -236.9 -50.8 -18.5 3.6
6.0E+02 -44.0 0.3 -0.4 -30.8 -126.5 -27.7 21.3 -0.8
6.0E+03 19.3 58.7 86.2 40.9 -113.0 44.6 73.3 14.4  
 
